<!DOCTYPE html>
<html lang="en">
<head>
    <meta charset="utf-8">
    <meta http-equiv="X-UA-Compatible" content="IE=edge">
    <meta content="width=device-width, initial-scale=1, maximum-scale=1, user-scalable=no" name="viewport">
    <meta name="description" content="نظام معلومات الأدوية السعودي Saudi Drugs Information System">
    <meta name="author" content="Saudi Food & Drug Authority (SFDA)">
    <noscript><meta http-equiv="refresh" content="0; url=/noScript.html" /></noscript>
    <link rel="shortcut icon" href="/favicon.ico">
    <title>&#x646;&#x638;&#x627;&#x645; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x623;&#x62F;&#x648;&#x64A;&#x629;</title>
    <link href="/fonts/roboto/roboto.css?v=53F8z0aw8DRnG9ou9x1tuKMPbNjRZWM-VBHl3B0s9-o" rel="stylesheet" />
    <link href="/fonts/material-icons/materialicons.css?v=8pEJ8MWsFzHRDLY0NI5rssf6T6vankxrJDPnnZxOGrg" rel="stylesheet" />
    <link href="/lib/bootstrap/dist/css/bootstrap-rtl.css?v=0env-Atj9mTPLILmJGwuDlLIOS_Akxxy4gnH1UUtrjU" rel="stylesheet" />
    <link href="/lib/bootstrap/dist/css/bootstrap-glyphicons.css?v=U5a39oen_WYzVAAexH5aoahbpqlKHcIzQrnXujf1yio" rel="stylesheet" />
    <link href="/lib/bootstrap-select/dist/css/bootstrap-select.css?v=DeY2lH0e0tmNnO9XZ-gGVOGk6_YoWlZ49y7CnD3ST00" rel="stylesheet" />
    <link href="/lib/toastr/toastr.css?v=kKePN_CyxTiMEgsSDu_7z21ru07YOZtR-0UV0JOkt5o" rel="stylesheet" />
    <link href="/lib/famfamfam-flags/dist/sprite/famfamfam-flags.css?v=JVJiF3s2_kk99xQHfYhfxo_-Dd52ZIruDMOILwPkqv0" rel="stylesheet" />
    <link href="/lib/font-awesome/css/font-awesome.css?v=YIHlqxkiJtENTMuzIHC9EfZaB5RniGr7kF7juUQJUuc" rel="stylesheet" />
    <link href="/lib/Waves/dist/waves.css?v=nd3hxjNg6DhkuFIz5IbxLK8Xw2ac0blsDQpF4pkJxUc" rel="stylesheet" />
    <link href="/lib/animate.css/animate.css?v=IT6GQizZpVcaM1_L_mIiNAYVvZErMgfwewf1GGWXG_I" rel="stylesheet" />
    <link href="/css/materialize.css?v=ey-J3xahkqficOYUHVX3jexmzvRFrge9bmux4CQr1DQ" rel="stylesheet" />
    <link href="/css/Publicstyle.css?v=xhOiVjq-54ODzSIeHXoascHsEJm_n_bIHqZatpxnYhg" rel="stylesheet">
    <link href="/css/Comman.css?v=bcS6_IRqBsBcY1mS_iriWWanrYR0Scdo1ffk8rQGXwQ" rel="stylesheet" />
    <link href="/css/themes/all-themes.css?v=eGSl5zNTWrXYfUx_EJW9ksC3CUTUUxvxmPiA3aQDtQo" rel="stylesheet" />
    <link href="/view-resources/Views/Shared/_Layout.css?v=BLxBuNISlF2O5EBHWdsX039NvnIHy-GtcqeI_MbyIc0" rel="stylesheet" />
    <link href="/lib/enjoyhint/enjoyhint.css?v=rSxIyBbiAvx_48ZcFxbn2DNPCCgEc0FXa2Vb72enxk4" rel="stylesheet" />
    <link href="/lib/dropzone/dropzone.css?v=IQDlHJdeYZ4gMH87EuB1yEG7ujA7DSEkV_SWfACk8Rg" rel="stylesheet" />

    <!-- View specific styles -->
    
    <script type="text/javascript" nonce="c7f26c8w">
        // This is used to get the application's root path from javascript. It's useful if you're running application in a virtual directory under IIS.
        var abp = abp || {};
        abp.appPath = '/';

    </script>
    <style>
        .popover .popover-title {
            text-align: right;
            font-weight: bold;
        }
        .popover .popover-content {
            text-align: right;
            font-size: 14px;
            font-family: 'Almarai', sans-serif;
            color: black;
        }
       
    </style>
</head>
<body>
    <!-- Page Loader -->
    <div class="page-loader-wrapper">
        <div class="loader">
            <div class="preloader">
                <div class="spinner-layer pl-blue">
                    <div class="circle-clipper left">
                        <div class="circle"></div>
                    </div>
                    <div class="circle-clipper right">
                        <div class="circle"></div>
                    </div>
                </div>
            </div>
            <p>&#x628;&#x631;&#x62C;&#x627;&#x621; &#x627;&#x644;&#x625;&#x646;&#x62A;&#x638;&#x627;&#x631; ...</p>
        </div>
    </div>
    <!-- #END# Page Loader -->
    <!-- Overlay For Sidebars -->
    <div class="overlay"></div>
    <!-- #END# Overlay For Sidebars -->
    <!-- Search Bar -->
    <!-- Top Bar -->
    <nav class="navbar navbar-inverse naav" style="margin-bottom: 0;">
        <div class="container-fluid">
            <div class="navbar-header">
                <button type="button" class="navbar-toggle" data-toggle="collapse" data-target="#myNavbar">
                    <span class="icon-bar"></span>
                    <span class="icon-bar"></span>
                    <span class="icon-bar"></span>
                </button>
            </div>
            <div class="collapse navbar-collapse rtl" id="navbar-collapse">
                <ul class="nav navbar-nav navbar-right">
                    <li><a href="/home/DrugSearch">&#x627;&#x644;&#x623;&#x62F;&#x648;&#x64A;&#x629;</a></li>
                        <li><a href="/Account/Login"><i class="fa fa-key"></i>&nbsp;&#x62A;&#x633;&#x62C;&#x64A;&#x644; &#x627;&#x644;&#x62F;&#x62E;&#x648;&#x644;</a></li>
                </ul>
                <ul class="nav navbar-nav navbar-left">
                    <li class="dropdown">
    <a href="javascript:void(0);" class="dropdown-toggle" data-toggle="dropdown" role="button">
        <i class="famfamfam-flags sa" title="&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;"></i>
        <span>&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;</span>
        <b class="caret"></b>
    </a>
    <ul class="dropdown-menu pull-right">
                <li><a href="/AbpLocalization/ChangeCulture?cultureName=en"><i class="famfamfam-flags gb"></i> English</a></li>

    </ul>
</li>

                </ul>
            </div>
        </div>
    </nav>
    <section id="mainContent" class="content">
        <nav class="navbar naav" style="margin-bottom: 0;">
            <div class="container-fluid">
                <ul class="nav navbar-nav">
                    <li>
                        <a class="text-center" href="/">
                            <img src="/images/logo_sdi.png" style="margin: auto;" width="250">
                        </a>
                    </li>
                </ul>
                <div class="navbar-header navbar-toggle2 ">
                    <button type="button" class="navbar-toggle navbar-toggle2" data-toggle="collapse"
                            data-target="#myNavbar2">
                        <span class="icon-bar icon-bar2 "></span>
                        <span class="icon-bar icon-bar2"></span>
                        <span class="icon-bar icon-bar2"></span>
                    </button>
                </div>
                <div class="collapse navbar-collapse " id="myNavbar2">
                    <ul class="nav navbar-nav">
                        <li>
                            <a href="#" class="text-right waves-effect" data-trigger="focus"
                               style="color: #4276a1;" data-container="body" data-toggle="popover" data-placement="bottom" title="" data-content="موقع الكترونى يمكن شركات ووكلاء الادويه من رفع النشرات الممارس الصحى ونشرة معلومات المريض وصورة عبوة الدواء المعتمدة من الهيئة العامة للعذاء والدواء بهدف بناء مرجع وطنى للادوية المسجلة يمكن الرجوع له من قبل الممارس الصحى والمريض كمصدر موثوق للمعلومات الدوائية"
                               data-original-title="&#x645;&#x646; &#x646;&#x62D;&#x646;">
                                &#x645;&#x646; &#x646;&#x62D;&#x646;
                            </a>
                        </li>
                        <li>
                            <a href="#" class="text-right waves-effect" data-trigger="focus"
                               style="color: #4276a1;" data-container="body" data-toggle="popover"
                               data-placement="bottom"
                               title=""
                               data-content="&#x627;&#x630;&#x627; &#x643;&#x627;&#x646; &#x644;&#x62F;&#x64A;&#x643;&#x645; &#x645;&#x644;&#x627;&#x62D;&#x638;&#x627;&#x62A; &#x627;&#x648; &#x627;&#x642;&#x62A;&#x631;&#x627;&#x62D;&#x627;&#x62A; &#x64A;&#x631;&#x62C;&#x649; &#x627;&#x644;&#x62A;&#x648;&#x627;&#x635;&#x644; &#x639;&#x644;&#x649;   SDI@SFDA.GOV.SA"
                               data-original-title="&#x62A;&#x648;&#x627;&#x635;&#x644; &#x645;&#x639;&#x646;&#x627;">
                                &#x62A;&#x648;&#x627;&#x635;&#x644; &#x645;&#x639;&#x646;&#x627;
                            </a>
                        </li>

                    </ul>
                </div>
            </div>
        </nav>
        

<div class="col-xs-12">
    <div class="row text-center">
        <a href="/" class="btn bg-blue btn-lg m-b-10 hover-white">&#x628;&#x62D;&#x62B; &#x62C;&#x62F;&#x64A;&#x62F;</a>
    </div>
</div>
<div class="jumbotron" style="margin-bottom: 0px; background-color: white !important;">
    <h3 class="text-center" style="color: #57aabf; ">Search Results</h3>
    <hr width="20%" style="border-top: 3px solid #54ae90;">

    <br>
    <table class="table s-row">
        <thead style="margin-bottom: 30px !important">
                <tr>
                    <th id="M" style="color:white;">
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x627;&#x644;&#x645;&#x645;&#x627;&#x631;&#x633; &#x627;&#x644;&#x635;&#x62D;&#x64A;</a>
                    </th>
                    <th id="A" style="color:white;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x645;&#x631;&#x64A;&#x636; &#x628;&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;</a>
                    </th>
                    <th id="E" style="color:white;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x645;&#x631;&#x64A;&#x636; &#x628;&#x627;&#x644;&#x627;&#x646;&#x62C;&#x644;&#x64A;&#x632;&#x64A;&#x629;</a>
                    </th>
                    <th id="f" class="active-tab" type='button'>
                        <a href="javascript:void(0)" style="color: white;">&#x635;&#x648;&#x631; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</a>
                    </th>
                    <th id="D" style="color:white; background-color: #47a4ba;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x628;&#x64A;&#x627;&#x646;&#x627;&#x62A; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</a>
                    </th>

                </tr>
        </thead>
    </table>
    <div id="D-div" class="box-data" style="display: block;">
        <div class="row">

<div class="modal-body rtl">
    <div class="tab-content">
        <div role="tabpanel" class="tab-pane m-r-60  animated fadeIn active" id="edit-user-details">
<div class="row clearfix">
                    <div class="col-lg-6 col-md-6 col-sm-6">
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="RegisterNumber">&#x631;&#x642;&#x645; &#x627;&#x644;&#x62A;&#x633;&#x62C;&#x64A;&#x644;</label>
                                    <div class="form-line">
                                        303-212-14
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="RegisterYear">&#x633;&#x646;&#x629; &#x627;&#x644;&#x62A;&#x633;&#x62C;&#x64A;&#x644;</label>
                                    <div class="form-line">
                                        2014
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="TradeName">&#x627;&#x644;&#x627;&#x633;&#x645; &#x627;&#x644;&#x62A;&#x62C;&#x627;&#x631;&#x64A;</label>
                                    <div class="form-line">
                                        RESPIRA Diskair 50/250
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="ScientificName">&#x627;&#x644;&#x627;&#x633;&#x645; &#x627;&#x644;&#x639;&#x644;&#x645;&#x64A;</label>
                                    <div class="form-line">
                                        FLUTICASONE PROPIONATE, SALMETEROL
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label " for="Strength">&#x627;&#x644;&#x62A;&#x631;&#x643;&#x64A;&#x632;</label>
                                    <div class="form-line">
                                        50, 250
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="StrengthUnitName">&#x648;&#x62D;&#x62F;&#x629; &#x627;&#x644;&#x62A;&#x631;&#x643;&#x64A;&#x632;</label>
                                    <div class="form-line">
                                        µg
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="AdministrationRouteName">&#x637;&#x631;&#x64A;&#x642;&#x629; &#x627;&#x644;&#x625;&#x633;&#x62A;&#x639;&#x645;&#x627;&#x644;</label>
                                    <div class="form-line">
                                        Inhalation use
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PharmaceuticalFormName">&#x627;&#x644;&#x634;&#x643;&#x644; &#x627;&#x644;&#x635;&#x64A;&#x62F;&#x644;&#x627;&#x646;&#x64A;</label>
                                    <div class="form-line">
                                        Inhalation powder, pre-dispensed
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="Size">&#x627;&#x644;&#x62D;&#x62C;&#x645;</label>
                                    <div class="form-line">
                                        60
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="SizeUnitName">&#x648;&#x62D;&#x62F;&#x629; &#x627;&#x644;&#x62D;&#x62C;&#x645;</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PackageSize">&#x62D;&#x62C;&#x645; &#x627;&#x644;&#x639;&#x628;&#x648;&#x629;</label>
                                    <div class="form-line">
                                        1
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PackageTypeName">&#x627;&#x646;&#x648;&#x627;&#x639; &#x627;&#x644;&#x639;&#x628;&#x648;&#x627;&#x62A;</label>
                                    <div class="form-line">
                                        Inhaler
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="LegalStatusName">&#x637;&#x631;&#x64A;&#x642;&#x629; &#x627;&#x644;&#x635;&#x631;&#x641;</label>
                                    <div class="form-line">
                                        Prescription
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="ProductControlName">&#x62D;&#x627;&#x644;&#x629; &#x627;&#x644;&#x645;&#x631;&#x627;&#x642;&#x628;&#x629;</label>
                                    <div class="form-line">
                                        Uncontrolled
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="DrugTypeName">&#x646;&#x648;&#x639; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</label>
                                    <div class="form-line">
                                        Generic
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="ShelfLife">&#x645;&#x62F;&#x629; &#x627;&#x644;&#x635;&#x644;&#x627;&#x62D;&#x64A;&#x629; &#x628;&#x627;&#x644;&#x623;&#x634;&#x647;&#x631;</label>
                                    <div class="form-line">
                                        24
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="StorageConditionsName">&#x634;&#x631;&#x648;&#x637; &#x627;&#x644;&#x62A;&#x62E;&#x632;&#x64A;&#x646;</label>
                                    <div class="form-line">
                                        store below 30°c
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="Price">&#x633;&#x639;&#x631; &#x627;&#x644;&#x62C;&#x645;&#x647;&#x648;&#x631; &#x628;&#x627;&#x644;&#x631;&#x64A;&#x627;&#x644;  ( &#x627;&#x644;&#x633;&#x639;&#x631; )</label>
                                    <div class="form-line">
                                        108.75
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <input type="hidden" id="Manufacture_NameEn" name="Manufacture.NameEn" value="GLAXOWELLCOME" />
                                        <label class="form-label" for="Manufacture_NameEn">&#x627;&#x644;&#x645;&#x635;&#x646;&#x639;</label>
                                        <div class="form-line">
                                            GLAXOWELLCOME
                                        </div>
                                    </div>
                                </div>
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <input type="hidden" id="Agent" name="Agent" value="[Agent 488]" />
                                        <label class="form-label">&#x627;&#x644;&#x648;&#x643;&#x64A;&#x644;</label>
                                        <div class="form-line">
                                            SPIMACO
                                        </div>
                                    </div>
                                </div>
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <label class="form-label" for="Company_NameEn">&#x627;&#x644;&#x634;&#x631;&#x643;&#x629; &#x627;&#x644;&#x645;&#x633;&#x648;&#x642;&#x629;</label>
                                        <div class="form-line">
                                            SPIMACO ADDWAEIH
                                        </div>
                                    </div>
                                </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="AtcCode1">&#x643;&#x648;&#x62F; &#x627;&#x644;&#x643;&#x64A;&#x645;&#x64A;&#x627;&#x621; &#x627;&#x644;&#x639;&#x644;&#x627;&#x62C;&#x64A;&#x629; &#x627;&#x644;&#x62A;&#x634;&#x631;&#x64A;&#x62D;&#x64A;&#x629; 1</label>
                                    <div class="form-line">
                                        R03AK06
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="AtcCode2">&#x643;&#x648;&#x62F; &#x627;&#x644;&#x643;&#x64A;&#x645;&#x64A;&#x627;&#x621; &#x627;&#x644;&#x639;&#x644;&#x627;&#x62C;&#x64A;&#x629; &#x627;&#x644;&#x62A;&#x634;&#x631;&#x64A;&#x62D;&#x64A;&#x629; 2</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                        </div>
                    </div>
                </div>
        </div>
    </div>
</div>

        </div>
    </div>
    <div id="E-div" class="box-data">
<div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue  m-t-20 m-b-20 ltr">
                <i class="fa fa-info-circle"></i>&nbsp;
                <span style="font-size: large; background-color: rgb(245,245,245); color: rgb(51,51,51); "> SFDA PIL</span>
                <span style="font-size:small;">  (Patient Information Leaflet (PIL) are under review by Saudi Food and Drug Authority)</span>

            </div>
</div>


<div class="clearfix ltr">
    <div class="col-lg-12 col-md-12 col-sm-12 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="InventedNameEn">1. What this product is and what it is used for</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Respira Diskair contains two medicines, salmeterol and fluticasone propionate:&nbsp;</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Salmeterol is a (long-acting beta2 agonist) bronchodilator. Bronchodilators help the airways in the lungs to stay open. This makes it easier for air to get in and out. The effects last for at least 12 hours.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Fluticasone propionate is a corticosteroid which reduces swelling and irritation in the lungs.</p><p>The doctor has prescribed this medicine to help prevent breathing problems such as:</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Asthma</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Chronic Obstructive Pulmonary Disease (COPD).</p><p>You must use Respira every day as directed by your doctor. This will make sure that it works properly in controlling your asthma or COPD.&nbsp;</p><p>Respira helps to stop breathlessness and wheeziness coming on. It does not work once you are breathless or wheezy. If that happens, you need to use a fast acting &lsquo;reliever&rsquo; medication, such as salbutamol.</p><p>Ask your doctor or pharmacist if you would like any further explanation about these uses.</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="form-group clearfix">
            <label style="float: left" class="h2" for="PrecautionsEn">2. What you need to know before you use this product</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p><strong>Do not take Respira Diskair:</strong></p><p>You are allergic (hypersensitive) tosalmeterol, fluticasone propionate or to the other ingredient in Respira Diskair.</p><p>&nbsp;</p><p>If you are not sure, talk to your doctor or pharmacist before takingRespira Diskair.</p><p>&nbsp;</p><p><strong>Take special care with Respira Diskair</strong></p><p>Check with your doctor or pharmacist before takingRespira Diskairif:</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; You have acute symptoms (use fast reliever bronchodilator)</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; You have overactive thyroid gland</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; You are using asthma relievers so frequent</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; You have or previously had tuberculosis</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; You have high blood pressure</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; You have Heart disease, including an irregular or fast heart beat</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; You have kidney problems, if your doctor transferring you from oral to inhaled cortisone</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; You have diabetes mellitus</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; You have low potassium in your blood</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; The current dose of Respira failed to give adequate control of asthma</p><p>If you are stopping the treatment do not to stop abruptly due to the risk of the symptoms worsening.</p><p>If you are suffering from COPD your doctor will be alert when prescribing Respira for pneumonia.</p><p>If you have sudden and progressive deterioration in control of asthma (it is life threatening), you should contact your doctor and he might increase the cortisone dose.</p><p>Increasing the use of fast reliever bronchodilator is indicator for case deterioration.</p><p>Your treatment plan will be titrated to the lowest dose that gives an effective control and maintain it.</p><p>If your child is asthmatic and treated with Respira, his height will be monitored by his doctor.</p><p>You should carry steroid warning card if are transferring from systemic to inhaled therapy.</p><p>You should discontinue Respira if you feel increase in wheezing after taking dose, and take immediately fast and short acting bronchodilator.</p><p>If your heart rate gets faster, this will be transient effect and tend to reduce with regular therapy.</p><p>If you are not sure if any of the above applies to you, talk to your doctor, pharmacist before using Respira Diskair.</p><p><strong>Giving other medicines, herbal or dietary supplements</strong></p><p>Please tell your doctor or pharmacist if you are taking or have recently taken any other medicines. This includes medicines for asthma or any medicines that you buy without a prescription and herbal medicines. This is because Respira Diskair can affect the way some medicines work. Also some other medicines can affect the way Respira Diskair works.</p><p>In particular, tell your doctor, pharmacist if you are taking any of the following medicines:</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Beta blockers, such as propranolol used to treat irregular or fast heart beats.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Antiviral and antifungal medicines (such as ritonavir, and ketoconazole).</p><p>&nbsp;</p><p>If you are not sure if any of the above applies to you, talk to your doctor or pharmacist before using Respira Diskair.</p><p>&nbsp;</p><p><strong>Pregnancy and breast-feeding</strong></p><p>As with all medicines, do not use Respira if you are pregnant, especially in the first 3 months, unless considered essential by your doctor.</p><p>Talk to your doctor or pharmacist before taking Respira if you are or might be pregnant or lactating.</p><p>Ask your doctor for advice before taking any medicine.</p><p><strong>&nbsp;</strong></p><p><strong>Effects on ability to drive and use machines</strong></p><p>Respirahas no reports on affecting your ability to drive or use any tools or machines.</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="AdministrationRoutesEn">3. How to use this product.</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Always take Respira Diskair exactly as your doctor has told you. You should check with your doctor or pharmacist if you are not sure. The dose has been prescribed will depend on the treatment plan.</p><p><strong>How to take Respira Diskair</strong></p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Do not increase the dose without medical advice.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Respira Diskair is administered by the oral inhaled route only.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Use Respira Diskair regularly for optimum benefit.</p><p>&nbsp;</p><p>Changing from corticosteroid alone to combination therapywill make you benefit either by more control of asthma or decreasing the dose of corticosteroid</p><p><strong>&nbsp;</strong></p><p><strong>Asthma</strong></p><p><strong>Adults and adolescents 12 years and older:-</strong></p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Respira 50/100 Diskair - One inhalation twice a day</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Respira 50/250 Diskair - One inhalation twice a day</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Respira 50/500 Diskair - One inhalation twice a day</p><p><strong>Children 4 years and older:-</strong></p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Respira 50/100 Diskair - One inhalation twice a day</p><p><strong>Children under 4 years:</strong></p><p>No data available for use of RESPIRA in children aged less than 4 years.</p><p>&nbsp;</p><p>Your symptoms may become well controlled using Respira twice a day. If so, your doctor may decide to reduce your dose to once a day.</p><p>&nbsp;</p><p><strong>Chronic Obstructive Pulmonary Disease (COPD)</strong></p><p><strong>Adult:</strong></p><p>Respira 50/250 to 50/500 Diskair - One inhalation twice a day</p><p>&nbsp;</p><p>It is very important to follow your doctor&rsquo;s instructions on how many inhalations to take and how often to take your medicine.</p><p>&nbsp;</p><p><strong>If your asthma or breathing gets worse tell your doctor straight away</strong>. You may find that you feel more wheezy, your chest feels tight more often or you may need to use more of your fast acting &lsquo;reliever&rsquo; medicine. If any of these happen, you should continue to take Respira but do not increase the number of puffs you take. Your chest condition may be getting worse and you could become seriously ill. See your doctor as you may need additional treatment.</p><p><strong>&nbsp;</strong></p><p><strong>Special patient group</strong></p><p>There is no need to adjust the dose in the elderlyor in those with kidney or liver problems.</p><p><strong>&nbsp;</strong></p><p><strong>If you use more Respira Diskair than you should</strong></p><p>If you use more Respira Diskair than you should, talk to a doctor or go to a hospital straight away. Take the medicine pack with you.</p><p><strong>The following effects may happen:</strong></p><p>Effects due to Salmeterol</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Your heart beating may be faster than usual.</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; You feel shaky.</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Your blood pressure becomes high.</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; You may have headache, muscle weakness, and joints ache.</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Your blood potassium become low</p><p>Effects due to Fluticasone</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Temporary suppression to HPA axis</p><p>Respira Diskair may affect the normal production of steroid hormones in the body, particularly if you have taken high doses for long periods of time particularly in children. The effects include:</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Your blood glucose becomes low (lead to unconsciousness and convulsions) this is triggered by stress (Trauma, Surgery, Infection or rapid reduction in dosage of corticosteroid)</p><p>&nbsp;</p><p>Your doctor will check you regularly for any of these side effects to give you the lowest dose of Respira to control your asthma.</p><p>&nbsp;</p><p>&nbsp;</p><p>If you have used larger doses for a long period of time, you should talk to your doctor or pharmacist for advice. This is because larger doses of Respira may reduce the amount of steroid hormones produced by the adrenal gland.</p><p><strong>&nbsp;</strong></p><p><strong>If you forget to take Respira Diskair</strong></p><p>If you miss a dose:</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; take Respira Diskair as soon as possible, then</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; take your next dose at the usual time</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; do not give a double dose to make up for a forgotten dose</p><p>&nbsp;</p><p><strong>Stopping taking Respira Diskair</strong></p><p>Do not stop taking Respira Diskair without talking to your doctor. Continue until the treatment is finished, even if you feel better.</p><p>&nbsp;</p><p>If you have any further question on the use of this product, ask your doctor or pharmacist.</p><p>&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="SideEffectsEn">4. Possible side effects</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Like all medicines, Respira Diskair can cause side effects, although not everybody gets them.</p><p><strong>Allergic reactions </strong></p><p>If you have an allergic reaction, stop taking Respira and see a doctor straight away. The signs may include:</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; sudden wheezing and chest pain or chest tightness</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; swelling of your eyelids, face, lips, mouth or tongue</p><p>&nbsp;</p><p>Other side effects are listed below:</p><p><strong>Very common (affects more than 1 in 10 people) </strong></p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Headache.</p><p><strong>Common (affects more than 1 in 100 people and less than 1 in 10 people)</strong></p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Fungal infection caused by Candida in the mouth (Thrush) and throat,lung infection in COPD patients. Muscle cramps, joints pain.</p><p><strong>Uncommon (affects more than or equal to 1 in 1000 people and less than 1 in 100 people) </strong></p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Rash</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Skin allergic reactions</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; shortness of breath</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; increased blood sugar</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Collection of blood in the tissue (contusions).</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Increased and irregular heartbeats.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Tremors</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Anxiety, sleep disorder</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Low potassium in blood</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Opacity in eye lens</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Horse voice, Throat irritation</p><p><strong>Rare (affects more than or equal to 1 in 10000 people and less than 1 in 1000 people) </strong></p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Allergic reactions including serious allergic reaction causing swelling of the face, tongue or throat which may cause difficulty in swallowing or breathing, itchy, bumpy rash (hives), chest tightness causing difficulty in breathing, Low blood pressure that can cause light-headedness on standing up and collapse.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Pressure in the eye</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Change in mood including irritability and increased activity (mainlyin children)</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Chest tightness causing difficulty in breathingor wheezing.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Fast heartbeats</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Swelling in the face and neck</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Cushing&rsquo;s syndrome, Cushingoid features, adrenal suppression, slowing the growth in children and adolescents, bone thinning.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Fungal infection caused by Candida in the oesophagus (gullet), which might cause difficulties in swallowing.</p><p>&nbsp;</p><p>If your asthma gets worse straight after taking Respira, stop using your Respira Diskair. Use your fast-acting &lsquo;reliever&rsquo; inhaler to help your breathing and tell your doctor straight away.</p><p>&nbsp;</p><p>If any of the side effects gets serious, or if you notice any side effects not listed in this leaflet, please contact your doctor or pharmacist.</p><p><strong>&nbsp;</strong></p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="StorageConditionsEn">5. How to store this product</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <strong>Keep out of the reach and sight of children.</strong></p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Do not use Respira Diskair after the expiry date which is stated on the pack after &lsquo;Exp&rsquo;.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Store Respira Diskair in dry place at below30&deg;C.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; If your doctor tells you to stop taking Respira Diskair, it is important to return any remnants which are left over to your pharmacist.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Medicines should not be disposed of via wastewater or household waste. Ask your pharmacist how to dispose of medicines no longer required. These measures will help to protect the environment.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">6. Further information</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="IngredientsEn">a. What this product contains</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p><strong>What Respira Diskair contains</strong></p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Active ingredients:</p><p><strong><em>Respira Diskair 250</em></strong> contains 50 micrograms salmeterol (as salmeterol xinafoate) and 250micrograms fluticasone propionate.</p><p>&nbsp;</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Other non active ingredients:</p><p>Lactose monohydrate (which contains milk proteins).</p><p>&nbsp;</p><p><strong>Instructions for use</strong></p><p>&nbsp;</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Your doctor, nurse or pharmacist should show you how to use your Diskair. They should check how you use it from time to time. Not using the Respira Diskair properly or as prescribed may mean that it will not help your asthma or COPD as it should.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; The Diskair releases a powder which is inhaled into the lungs.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Open and prime the device by sliding the lever.&nbsp;</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Place the mouthpiece in the mouth and close the lips around it.&nbsp; Then inhale the dose and the close the device.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; A dose indicator on the Diskair indicates the number of doses left.</p><p>&nbsp;</p><p><strong>Instructions for using your Respira Diskair:</strong></p><p><strong>Closed:</strong></p><p>When you take your Diskair out of its box, it will be in the closed position.</p><p><img alt="" width="208" height="177" src="data:image/png;base64,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" /></p><p><strong>OPENED</strong></p><p>A new Diskair contains 28 or 60 doses individually protected doses of your medicine, in powder form.&nbsp; The dose indicator tells you how many doses are left.</p><p><img alt="" width="192" height="168" src="data:image/png;base64,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" /></p><p>Each dose is accurately measured and hygienically protected.&nbsp; It requires no maintenance - and no refilling.</p><p>The dose indicator on top of your Diskair tells you how many doses are left. Numbers 5 to 0 will appear in RED, to warn you when there are only a few doses left.</p><p>The Diskair is easy to use. When you need a dose, just follow the five steps illustrated:</p><p>1. Open.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</p><p>2. Slide.</p><p>3. Inhale.</p><p>4. Close.</p><p>5. Rinse.</p><p>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</p><p><strong>How your Diskair works</strong></p><p>Sliding the lever of your Diskair opens a small hole in the mouthpiece and unwraps a dose, ready for you to inhale it. When you close the Diskair, the lever automatically moves back to its original position, ready for your next dose when you need it. The outer case protects your Diskair when it is not in use.</p><p>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; 1.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Open - How to use the Diskair.</p><p>To open your Diskair, hold the outer case in one hand and put the thumb of your other hand on the thumb grip. Push your thumb away from you as far as it will go.</p><p><img alt="" width="296" height="330" src="data:image/png;base64,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" /></p><p>2.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Slide.</p><p>Hold your Diskair with the mouthpiece towards you. Slide the lever away from you, as far as it will go - until it clicks. Your Diskair is now ready to use. Every time the lever is pushed back, a dose is made available for inhaling. This is shown by the dose counter. Do not play with the lever as this releases doses which will be wasted.</p><p><img alt="" width="305" height="350" src="data:image/png;base64,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" /></p><p>3.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Inhale</p><p>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; - Before you start to inhale the dose, read through this section carefully.</p><p>- Hold the Diskair away from your mouth. Breathe out as far as is comfortable. Remember - never breathe into your Diskair.</p><p>- Put the mouthpiece to your lips. Breathe in steadily and deeply - through the Diskair, not through your nose.</p><p>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; - Remove the Diskair from your mouth.</p><p>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; - Hold your breath for about 10 seconds, or for as long as is comfortable.</p><p>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; - Breathe out slowly.</p><p><img alt="" width="295" height="314" src="data:image/png;base64,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" /></p><p>4.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Close</p><p>To close your Diskair, put your thumb in the thumb grip, and slide the thumb grip back towards you, as far as it will go.</p><p>When you close the Diskair, it clicks shut. The lever automatically returns to its original position and is reset. Your Diskair is now ready for you to use again.</p><p><img alt="" width="295" height="286" src="data:image/png;base64,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" /></p><p>5. &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Rinse</p><p>Afterwards, rinse your mouth with water and spit it out.</p><p>&nbsp;</p><p>If you have been instructed to take two inhalations you must close the Diskair and repeat stages 1 to 4.</p><p><strong>REMEMBER</strong></p><p>Keep your Diskair dry.</p><p>Keep it closed when not in use.</p><p>Never breathe into your Diskair.</p><p>Only slide the lever when you are ready to take a dose.</p><p>Do not exceed the stated dose.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ShapeAndContentsEn">b. What this product looks like and contents of the pack</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                •	Molded plastic device containing a foil strip with 28 or 60 regularly placed blisters each containing Inhalation powder for one dose.

Not all packs are available in every country.

            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ManufacturingAndMarketingEn">c. Marketing Authorization Holder and Manufacturer</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p><strong>Manufactured by:</strong></p><p>Glaxo Operations UK Ltd.* - Ware - UK</p><p><strong>Glaxo Wellcome Production, Evreux, France </strong></p><p><strong>Packed by</strong>: Glaxo Saudi Arabia Ltd. * - Jeddah &ndash; KSA</p><p>*member of the GlaxoSmithKline group of companies&nbsp;</p><p><strong>For:</strong></p><p>SPIMACO</p><p>Al-Qassim Pharmaceutical Plant</p><p>Saudi Arabia</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="RevisionNoteEn">d. This leaflet was last revised in {MM/YYYY}</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                28 February 2019
            </div>
        </div>
    </div>
</div>    </div>
    <div id="A-div" class="box-data">
<div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue  m-t-20 m-b-20 ltr">
                <i class="fa fa-info-circle"></i>&nbsp;
                <span style="font-size: large; background-color: rgb(245,245,245); color: rgb(51,51,51); "> نشرة الدواء تحت مراجعة الهيئة العامة للغذاء والدواء</span>
                <span style="font-size:small;">  (اقرأ هذه النشرة بعناية قبل البدء في استخدام هذا المنتج لأنه يحتوي على معلومات مهمة لك)</span>
            </div>
    <div class="p-10 bg-light-blue font-15 m-t-20 m-b-20 ltr">

    </div>

</div>
<div class="clearfix rtl">
    <div class="col-xs-12">
        <div class="form-group clearfix">
            <label class="h2" for="InventedNameAr">1. ما ھو هذا المستحضر وماھي دواعي استعماله</label>
        </div>
        <div class="form-group clearfix" style="float: right">
            <br />
            <p>رسبيرا ديسكيريحتوي على دوائين سالميتيرول وفلوتيكازون ﭘروﭘيونيت:</p><ul><li>السالميتيرول عبارة عن موسع للشعب (منشط طويل المفعول للمستقبلات الأدرينية بيتا-2). موسعات الشعب تساعد المجاري التنفسية في الرئة على أن تظل مفتوحة. و هذا يمكن الهواء من الدخول والخروج بسهولة. يستمر المفعول لمدة 12 ساعة على الأقل.</li><li>فلوتيكازون ﭘروﭘيونيت هو كورتيزون قشري كظري يقلل الانتفاخ و التهيج في الرئة</li></ul><p>وصف الطبيب هذا الدواء للمساعدة على منع مشاكل التنفس كما في:</p><ul><li>الربو</li><li>مرض الانسداد الرئوي المزمن (COPD)</li></ul><p>يجب أن تستعمل رسبيرا كل يوم كما أرشدك الطبيب. فذلك يضمن عمله بفعالية في التحكم بالربو أو (COPD)</p><p>رسبيرا يساعد على إيقاف ضيق التنفس و الأزيز. إنه لايعمل فور شعورك بضيق التنفس أو الأزيز. إذا حدث ذلك، تحتاج لاستعمال دواء مخفف للأعراض سريع المفعول، مثل سالبيوتامول.</p><p>اسأل طبيبك أو الصيدلي إذا أردت أي استفسارات أخرى عن هذه الاستعمالات.</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="form-group clearfix">
            <label class="h2" for="PrecautionsAr">2. ما الذي يجب عليك معرفته قبل استعمال هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p><strong>لا تتناول رسبيرا ديسكير إذا</strong><strong>:</strong></p><p>كنت مصاباً بحساسية (مفرط الحساسية) للسالميتيرول أوفلوتيكازون ﭘروﭘيونيت، أو أي من المكونات الأخرى في رسبيرا ديسكير.</p><p>&nbsp;</p><p>إذا لم تكن متأكداً، تحدث مع طبيبك أو الصيدلي قبل تناول رسبيرا ديسكير.</p><p>&nbsp;</p><p><strong>احتياطات خاصة عند استعمال رسبيرا ديسكير</strong></p><p>راجع مع طبيبك أو الصيدلي قبل تناول رسبيرا ديسكير إذا:</p><p>&nbsp;</p><p>&bull;كانت لديك أعراض حادة (استخدم مخفف للأعراض موسع للشعب سريع المفعول)<br />&bull; كان لديك فرط نشاط الغدة الدرقية<br />&bull; كنت تستخدم مخففات الربو بصورة متكررة<br />&bull; كان لديك حالياً أو تاريخ سابق للإصابة بالسل<br />&bull; كان لديك ارتفاع في ضغط الدم<br />&bull; كنت تعاني من أمراض القلب، بما في ذلك عدم انتظام أو سرعة في ضربات القلب<br />&bull; كان لديك مشاكل في الكلى، إذا كان طبيبك حول علاجك إلى كورتيزون مستنشق بدلاً من كورتيزون فموي<br />&bull; كان لديك مرض السكري<br />&bull; كان لديك انخفاض في مستوى البوتاسيوم في الدم<br />&bull; كانت الجرعة الحالية من رسبيرا فشلت في إعطاء تحكم كافي في الربو</p><p>&nbsp;</p><p>إذا كنت تتوقف عن العلاج لا توقفه فجأة بسبب المخاطر من تفاقم الأعراض.<br />سوف يكون طبيبك متنبهاً لاحتمال حدوث إلتهاب رئوي عند وصف رسبيرا إذا كنت تعاني من مرض الانسداد الرئوي المزمن.<br />إذا حدث لك تدهور مفاجئ ومتزايد في السيطرة على الربو (هذا يعتبرمهدد للحياة)، يجب عليك الاتصال بالطبيب ويحتمل أن يزيد جرعة الكورتيزون.<br />زيادة استخدام مخفف للأعراض موسع للشعب سريع المفعول هو مؤشر لتدهور الحالة.<br />سيتم معايرة الجرعة العلاجية الخاصة بك إلى أدنى جرعة تعطي تحكم فعال وتحافظ عليه.<br />إذا كان طفلك مصاباً بالربو ويعالج برسبيرا، سيتم مراقبة طوله من قبل طبيبه.<br />يجب أن تحمل بطاقة تحذير الستيرويد إذا تم تحويل علاجك من كورتيزون جهازي إلى كورتيزون مستنشق.<br />يجب عليك التوقف عن استخدام رسبيرا إذا كنت تشعر بزيادة في الأزيز بعد تناول جرعة، وتناول موسع للشعب سريع المفعول على الفور.<br />إذا تسارع معدل ضربات القلب، إن هذا تأثيراً عابراً ويميل إلى الإنخفاض مع استمرار العلاج.<br />&nbsp;</p><p>إذا لم تكن متأكداً إذا كان أى مما أعلاه ينطبق عليك، فتحدث مع طبيبك أو الصيدلي قبل تناول رسبيرا ديسكير.</p><p>&nbsp;</p><p><strong>تناول أدوية أخرى مع هذا الدواء، أو مستحضرات عشبية أو مدعمات غذائية</strong></p><p>فضلاً أخبر طبيبك أو الصيدلي إذا كنت تتناول أوتناولت أدوية أخرى منذ فترة قصيرة. ويشمل هذا الأدوية التي تشتريها بدون وصفة طبية والأدوية العشبية. يرجع هذا لأن رسبيرا ديسكير، قد يؤثر على طريقة عمل بعض الأدوية. وأيضاً بعض الأدوية الأخرى يمكن أن تؤثر في طريقة عمل رسبيرا ديسكير.</p><p>على وجه الخصوص، أخبر طبيبك أو الصيدلاني إذا كنت تتناول أي من الأدوية الآتية:</p><p>&bull; حاصرات بيتا، مثل پروپرانولول يستخدم لعلاج عدم انتظام أو سرعة ضربات القلب.<br />&bull; الأدوية المضادة للفيروسات ومضاد للفطريات (مثل ريتوناڤير، والكيتوكونازول).</p><p>&nbsp;</p><p>إذا لم تكن متأكداً إذا كان أى مما أعلاه ينطبق عليك، فتحدث مع طبيبك أو الصيدلي قبل تناول رسبيرا ديسكير.</p><p>&nbsp;</p><p><strong>الحمل والرضاعة الطبيعية</strong></p><p>كشأن جميع الأدوية، لاتستخدمي رسبيرا إذا كنت ِحامل، خاصة في الثلاثة شهور الأولى، إلا إذا اعتبر هذا ضرورياً من قبل الطبيب.</p><p>تحدثي مع طبيبك أو الصيدلي قبل تناول رسبيرا إذا كنت حاملا أو تخططين للحمل أو كنت تقومين بالرضاعة الطبيعية.</p><p>يجب استشارة الطبيب قبل تناول أي دواء.</p><p>&nbsp;</p><p><strong>التأثيرات على القدرةعلى القيادة واستخدام الآلات</strong></p><p>لم يرد ذكر أية تقارير عن تأثيررسبيرا ديسكير على القدرة على قيادة السيارات أو استخدام الآلات.</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            https://localhost:44358/Dashboard
            <label class="h2" for="AdministrationRoutesAr">3. ماھي طريقة استعمال هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p>تأكد دوماً من تناول رسبيرا ديسكير تماماً كما وصف لك الطبيب.راجع طبيبك أو الصيدلي إذا كنت غير متأكد. الجرعة التي تم وصفها لك تعتمد علي الخطة العلاجية لحالتك.</p><p><strong>كيف تتناول رسبيرا ديسكير</strong></p><ul><li>لا تزيد الجرعة دون استشارة طبية.</li><li>تناول رسبيرا ديسكيرعن طريق الإستنشاق عن طريق الفم فقط.</li><li>استخدم رسبيرا ديسكير بانتظام للحصول على الفوائد المثلى.</li></ul><p><br />التغيير من الكورتيكوستيرويد وحده إلى العلاج المجمع سوف يفيدك إما عن طريق زيادة السيطرة على الربو أو خفض جرعة الكورتيكوستيرويد.<br /><br /><strong>الربو<br />البالغين والمراهقين 12 سنة فما فوق:</strong><br />رسبيرا 50 ميكروجرام/100 ميكروجرام-نشقة واحدة مرتين في اليوم<br />رسبيرا 50 ميكروجرام/250 ميكروجرام- نشقة واحدة مرتين في اليوم<br />رسبيرا 50 ميكروجرام/500 ميكروجرام- نشقة واحدة مرتين في اليوم<br /><strong>أطفال في سن 4 سنوات فما فوق:</strong><br />رسبيرا 50 ميكروجرام/100 ميكروجرام- نشقة واحدة مرتين في اليوم<br /><strong>الأطفال دون سن 4 سنوات:</strong><br />لا توجد بيانات متاحة للاستخدام رسبيرا في الأطفال الذين تقل أعمارهم عن 4 سنوات.<br /><br />قد تكون السيطرة على الأعراض بشكل جيد باستخدام رسبيرا مرتين في اليوم. إذا كان الأمر كذلك، قد يقرر طبيبك خفض الجرعة إلى مرة واحدة في اليوم.<br /><br /><strong>مرض الانسداد الرئوي المزمن (</strong><strong>COPD</strong><strong>)<br />البالغين:</strong><br />رسبيرا50/250 إلى رسبيرا 50/500 ديسكير- نشقة واحدة مرتين في اليوم<br /><br />من المهم جداً اتباع تعليمات الطبيب حول عدد النشقات وكيفية تناول الدواء.<br /><br /><strong>إذا ساءت حالة الربو أو التنفس أخبر طبيبك على الفور.</strong>قد تجد أنك تشعر بأزيز بصورة أكبر، تشعر بضيق في الصدرفي كثير من الأحيان أو قد تحتاج لاستخدام دوائك المخفف للأعراض بصورة أكبر. إذا حدث هذا، يجب أن تستمر في تناول رسبيرا بدون زيادة عدد النشقات التي تأخذها. فقد تزداد حالة صدرك سوء او يمكن أن تصبح الحالة المرضية خطيرة. راجع طبيبك لأنك قد تحتاج إلى علاج إضافي.<br /><br /><strong>مجموعة خاصة من المرضى</strong><br />ليست هناك حاجة لتعديل الجرعة لدى كبار السن أو الذين يعانون من مشاكل في الكلى أو الكبد.</p><p><strong>&nbsp;</strong></p><p><strong>إذا تناولت رسبيرا ديسكير أكثر مما يجب</strong></p><p>إذا تناولت رسبيرا ديسكير أكثرمما يجب، تحدث مع طبيب أو اذهب للمستشفى على الفور. قم بأخذ علبة الدواء معك.</p><p><strong>قد تحدث الآثار التالية:</strong><br />الآثار الناجمة عن سالميتيرول<br />- قد تتسارع ضربات قلبك أكثر من المعتاد.<br />- تشعر برجفة.<br />- يصبح ضغط الدم المرتفع.<br />- قد تشعربصداع، وضعف العضلات، وآلام المفاصل.<br />- مستوى البوتاسيوم في الدم يصبح منخفض.<br />الآثار الناجمة عن فلوتيكازون<br />- تثبيط مؤقت للمحور الوِطائِيّ النخامي الكظري<br />رسبيرا ديسكير قد يؤثر على الإنتاج الطبيعي لهرمونات الستيرويد في الجسم، خاصة إذا كنت قد تناولت جرعات عالية لفترات طويلة من الزمن وخاصة في الأطفال. الآثار تتضمن ما يلي:<br />- مستوى السكر في الدم يصبح منخفض (يؤدي إلى فقدان الوعي والتشنجات) وهي مستحثة بالإجهاد (الجروح، الجراحة، عدوى أو انخفاض سريع في جرعة الكورتيكوستيرويد)<br /><br />سوف يتحقق طبيبك بانتظام عن أي من هذه الآثار الجانبية ليعطيك أقل جرعة من رسبيرا للسيطرة على الربو لديك.<br /><br />إذا كنت قد استخدمت جرعات أكبر لفترة طويلة من الزمن، يجب عليك التحدث مع طبيبك أو الصيدلي للحصول على المشورة. وذلك لأن الجرعات الأكبر من رسبيرا قد تقلل من كمية هرمونات الستيرويد التي تنتجها الغدة الكظرية.</p><p>&nbsp;</p><p><strong>إذا نسيت تناول رسبيرا ديسكير</strong></p><p>إذا فاتك جرعة:</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; يجب تناول رسبيرا ديسكيرفي أسرع وقت ممكن، ثم</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; يجب تناول الجرعة التالية في موعدها المعتاد.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; لا يجوز تناول جرعة مضاعفة للتعويض عن جرعة منسية.</p><p><strong>&nbsp;</strong></p><p><strong>التوقف عن تناول رسبيرا ديسكير</strong></p><p>لا تتوقف عن تناول رسبيرا ديسكير دون التحدث مع طبيبك. استمر حتى الانتهاء من العلاج، حتى لو كنت تشعر بتحسن.</p><p>&nbsp;</p><p>إذا كانت لديك أية أسئلة أخرى عن استعمال هذا المستحضر، اسأل الطبيب أو الصيدلي.</p><p>&nbsp;</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label class="h2" for="SideEffectsAr">4. الأعراض الجانبية المحتملة</label>
        </div>
        <div class="m-r-60">
            <p>كشأن كافة الأدوية، قد يتسبب رسبيرا ديسكيرفي بعض الأعراض الجانبية، إلا أنها لا تصيب جميع الأشخاص.</p><p><strong>ردود فعل تحسسية</strong><strong>:</strong></p><p>إذا حدثت لك حساسية، أوقف العلاج وقم بمراجعة الطبيب على الفور. قد تشتمل أعراض الحساسية على:</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; أزيز مفاجئ وألم في الصدر أو ضيق في الصدر</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; تورم الجفون أو الوجه أو الشفاه أو الفم أو اللسان</p><p>&nbsp;</p><p><strong>الأعراض الجانبية الأخرى تشتمل على ما يلي:</strong></p><p><strong>شائعة جداً</strong><strong> (</strong><strong>تؤثر على أكثر من 1 من بين 10 أشخاص</strong><strong>)</strong></p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; صداع.</p><p><strong>شائعة</strong><strong> (</strong><strong>تؤثر على أكثر من 1 من بين 100 شخص وأقل من 1من بين 10 أشخاص</strong><strong>)</strong></p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; عدوى فطرية تسببها المبيضات في الفم (القلاع) والحلق، والتهاب في الرئتين لدى مرضى السدة الرئوية المزمنة. تقلصات العضلات، وآلام المفاصل.</p><p><strong>غير شائعة</strong><strong> (</strong><strong>تؤثر على أكثر من أو شخص واحد من بين 1000 شخص وأقل من شخص واحد من بين 100 شخص</strong><strong>)</strong></p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; طفح جلدي</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; ردود فعل حساسية الجلد</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; ضيق في التنفس</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; زيادة في سكر الدم</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; تجمع الدم في الأنسجة (كدمات)</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; زيادة وعدم انتظام ضربات القلب</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; رجفان</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; القلق، واضطراب النوم</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; انخفاض مستوى البوتاسيوم في الدم</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; تعتيم في عدسة العين</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; صوت أجش وتهيج الحلق</p><p>&nbsp;</p><p><strong>نادرة</strong><strong> (</strong><strong>تؤثر على أكثر من 1 من بين 10000 شخص وأقل من 1 من بين 1000 شخص</strong><strong>)</strong></p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; الحساسية بما في ذلك ردود فعل تحسسية خطيرة مما يؤدي إلى التورم في الوجه أواللسان أو الحلق مما قد يسبب صعوبة في البلع أو التنفس، حكة، طفح (شرى)، ضيق الصدر مما يسبب صعوبة في التنفس، وانخفاض ضغط الدم الذي يمكن أن يسبب شعور بخفة في الرأس عند الوقوف قائماً وقد يتسبب في السقوط (الانهيار).</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; ضغط في العين</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; تغير في المزاج بما في ذلك التهيج وزيادة النشاط (غالباً في الأطفال)</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; ضيق في الصدر مما يسبب صعوبة في التنفس أو الأزيز.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; تسارع في ضربات القلب</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; تورم في الوجه والرقبة</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; متلازمة كوشينج، وظواهر كوشينجية، وتثبيط الغدة الكظرية، وتباطؤ النمو في الأطفال والمراهقين، ترقق العظام.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; عدوى فطرية تسببها المبيضات في المريء، يمكن أن تسبب صعوبة في البلع.<br />&nbsp;</p><p>إذا ساءت حالة الربو لديك مباشرة بعد تناول رسبيرا، توقف عن استخدام رسبيرا ديسكير. استخدام مخفف الأعراض سريع المفعول المستنشق للمساعدة على تنفسك وأخبر الطبيب على الفور.</p><p>&nbsp;</p><p>إذا ازدادت حدة أي من الأعراض الجانبية، أو لاحظت وجود أي عرض جانبي آخر غير مذكور في هذه النشرة، فضلاً تحدث مع طبيبك أو الصيدلي.</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label class="h2" for="StorageConditionsAr">5. طريقة تخزين المستحضر</label>
        </div>
        <div class="m-r-60">
            <p><strong>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </strong><strong>يحفظ بعيداً عن متناول ونظر الأطفال.</strong></p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; لا تستخدم رسبيرا ديسكير بع دتاريخ انتهاء الصلاحية المذكور على العبوة بعد كلمة &quot;Exp&quot;.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; يجب حفظ رسبيرا ديسكيرفي مكان جاف في درجة حرارة أقل من 30<sup>&deg;</sup> م.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إذا أخبرك الطبيب بوقف تناول رسبيرا ديسكير، فمن المهم أن تعيد ما تبقى إلى الصيدلي.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; لا ينبغي التخلص من الادوية عن طريق مياة الصرف الصحي أو المخلفات المنزلية. اسأل الصيدلي عن كيفية التخلص من الأدوية التي لم تعد بحاجة إليها. سوف تساعد هذه التدابير في حماية البيئة.</p>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: right">6. معلومات أخرى</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="IngredientsAr">أ‌. على ماذا يحتوي هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p><strong>على ماذا يحتوي رسبيرا ديسكير</strong></p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; المواد الفعالة:</p><p><strong><em>رسبيرا ديسكير 250</em></strong> يحتوي على 50 ميكروجرام سالميتيرول (على هيئة زينافويت) و250 ميكروجرام فلوتيكازون ﭘروﭘيونيت.</p><p>&nbsp;</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; مواد أخرى غير فعالة:</p><p>لاكتوز مونوهيدريت (والذي يحتوي بروتينات اللبن)</p><p>&nbsp;</p><p><strong>تعليمات خاصة بالاستعمال</strong><strong> / </strong><strong>التداول</strong></p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; الطبيب، الممرض أو الصيدلي يجب أن يشرح لك كيفية استخدام جهاز الديسكير الخاص بك. ينبغي أن يتحققوامن كيفية استخدامك له من وقت لآخر. عدم استخدام رسبيرا ديسكير بشكل صحيح أو كما هو مقرر قد يعني أنه لن يساعد في الشفاء من الربو، أو مرض الانسداد الرئوي المزمن كما يجب.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; جهاز ديسكير يطلق مسحوقاً يستنشق إلى داخل الرئتين.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; الجهاز يفتح ويضبط بتزليق الذراع.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; ضع قطعة الفم في الفم وأغلق الشفتين حولها. يمكن استنشاق الجرعة حينها وإغلاق الجهاز.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; مؤشر الجرعات على جهاز ديسكير يشير إلى عدد الجرعات المتبقية.</p><p><strong>&nbsp;</strong></p><p><strong>تعليمات لاستعمال جهاز رسبيرا ديسكير</strong></p><p><strong>مغلق:</strong></p><p>عندما تخرج جهاز ديسكير من علبته، سيكون في الوضع المغلق.</p><p>&nbsp;</p><p><img alt="" width="208" height="177" src="data:image/png;base64,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" /></p><p><strong>مفتوح</strong></p><p>جهاز ديسكير الجديد يحتوي على 28 أو 60 جرعة محفوظة بمفردها من دوائك، على شكل مسحوق. مؤشر الجرعة يبيّن لك عدد الجرعات المتبقية.</p><p><img alt="" width="192" height="168" src="data:image/png;base64,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" /></p><p>كل جرعة تم قياسها بدقة وحفظها بطريقة صحية. الجهاز لا يتطلب صيانة&ndash;ولا تعاد تعبئته.</p><p>مؤشر الجرعات أعلى جهاز ديسكير يبيّن لك عددالجرعات المتبقية. الأرقام 5 إلى صفر ستظهر باللون الأحمر، لتنبهك عندما لا يتبقى سوى جرعات قلائل فقط.</p><p>جهاز ديسكير سهل الاستخدام. عند احتياجك لجرعة، فقط اتبع الخمس خطوات البسيطة المبينة بالرسم؛</p><p>1- الفتح.</p><p>2- التزليق.</p><p>3- الاستنشاق.</p><p>4- الغلق.</p><p>5- المضمضة.</p><p>&nbsp;</p><p><strong>كيف يعمل جهاز ديسكير</strong></p><p>تزليق الذراع بجهاز ديسكير يفتح ﺜقباً صغيراً في قطعة الفم ويزيل غلاف الجرعة، بحيث تصبح جاهزة لتستنشقها. عندما تغلق جهاز ديسكير، ستعود الذراع تلقائياً إلى وضعها الأصلي، بحيث يصبح جاهزاً لاستنشاق جرعتك التالية عندما تحتاج إليها. العلبة الخارجية تحمي جهاز ديسكير في حالة عدم استخدامه.</p><p>1- الفتح &ndash; كيفية استعمال جهاز ديسكير</p><p>لفتح جهاز ديسكير، أمسك العلبة الخارجية بيد واحدة وضع إبهام يدك الأخرى على مقبض الإبهام. ادفع بالإبهام بعيداً عنك لأقصى حد ممكن.</p><p><img alt="" width="296" height="330" src="data:image/png;base64,iVBORw0KGgoAAAANSUhEUgAAASgAAAFKCAIAAAAhWVUfAAAAAXNSR0IArs4c6QAAAARnQU1BAACxjwv8YQUAAAAJcEhZcwAADsMAAA7DAcdvqGQAABY/SURBVHhe7dZZguUoDgXQ3v+mqzHSUxIYYyYxyPd8RNrMyFK9+t9/ADAdCg9gARQewAIoPIAFUHgAC6DwABZA4QEsgMIDWACFB7AACg9gARQewAIoPIAFUHgAC6DwABZA4QEsgMIDWACFB7AACg9gge8W3v/+4laAKT6XcFxnHjd53PSAB43D6wa4A77hQ9+7J79p7kC8boA7HvAgsOIrX3R++tKOhJtS7gOoxeF3j5tQgVYY/5Ccrd69xQkb6fmOegvxnDL58ckFqfGOu+EQBj8YZ6LHTc9kWMngTrIXiV6f0DDCTTfc/cOtsDFTH2nntIvO1nBOWsHh92c8zuMm2IyRD7N5ko09Hq1GuOkZj/uL+2AdC99g/0yKTjjwwFcZefz+LBxDUwS3wkTHB/2IvAnzW+PAtL7D75V48l/cBzrOju9B+SFHVT3zVTEev3eQdejBoWffCb3OjuNBeTDzqFeV/HBTk2g6LXjH3VDj7Kjhq+dRYTj8XqN8Fm1BuAneoPA+garC4fcyteOdhinfdHCYfCLhM9ehoN1xd0q+N0RLOfwOz86OEb7xKFQwDr//xX3P0Q576bkczfqas6/92c+mJ1MM1OXw+0/UImPkgZ7lb8gP+YM7rDv4nkd8Jzqkw++H4EM/HJv7frj156nFj+UHeXWuET/c5HGTUQdfb8NvQxkT4o5bF7dur+GoQ27ng/QPtxpi8EqTcWp43PSGR5+QT3zQAHc84EF9eK0AdxiqwLNvMudL0Cd/woOa9K+gKnk2OjPhpkCycRTa1OH3kx18h+YP8DrRf9x/uLVANLhwrt/kwu97KDkPHZvIK3XpoV0cfj/TwafvCb18OXqI0Jha0cTapWi8w++r1Z6EDu+Ez0k0vkE0t3O1tY49934Rj47UfMIrm3646RwlZ6arEW4qkBxcu8g+zjz0fuEOz0PP/Se8Lhng1lmad6ya6G9WNJ6G0XiHGp3o9RTnndjZLdDht6cHeR3Ib/IHd+ho20JpFvWGw6JnejjIgSfeL8rRkeac0O0S4Y5xGpZtmCIyc6n93utnXPj9HAeeeL8o73Akn35/cEefqqVoZPn4O79bYjq1O/z+V6ZrW6cdd8v4yqn2Od6ViX9xR5OSFWjA67ASyUXyK7ve/IDdnHRWZ8/gyqn81980pHQ2h98r8WSPmwLSmOxtEK1z7VqwcuGwHZxxSrFnWE/52I7PTMZNlXjyX9JFD/3CZUnh4jRRcOt+9j3Z3bZx3PkDE5+EF34flKDRxOZ1knoWl8HuoWriNDue6cmeESTbfmCn5GB0fsJNlZonZoRr1q4v491D7dwJtjtQxobhC+15vNpTXUmqP6VQuGzDFv5cPCt83sFGR3m1VeCO0JZtVbOqBtcKV27bxZ+udxENu5yjxD5RM+811Fc6e/yuI1y/eS9/zAHrjLXFIQptErKztAXtPsu1RLhDU7hLz46j1hloi0MU2iRkZ3FBa4gbTaG5hNonC/ftPEa0FD+ts/4EhXYI1qFqQ+fGbxJtOQYdyaHXNjK9f6l+W8S3xPJIHa0q1TYJdXhmepDXNn69fwvK8xIr966yNkwGFKZa4bAJwmPQqRx+bxUu0r9ajy1C/CqMF/SgSApu/eHWPUItx6CHUacK11l402UbV1kYIMNcVCPUSL1rhccYezC3jiwVPk+2Ztdaq6LTZuHn7LTJycMz0LM/17CDhUsNXLbKml1rTYvO9XlH7EXrJEW9NH4Hm5wnPMb9YQi/w78Fxy5eaMGWDSaHpm2762P+cFNKOICen9CYOebvmBQeQ56lZaBoTY0t8mbv12ZBXDx+eVM1uBCtmcQjuvFyHjctFR5DTiUPY0VrKu2SMXWzZpODIuh7JIW9NHgO3jLAHTfcncVD10WY3A9Dr/Iw3H1lpY2eTN2s2eSghJ62pvb5B3M7hpvSa1I4gJ7zCocNF51QXuVBQ3Jxve3u5u3UY2ZEiP8uF35/8DpguHBHeg7/hg9O+FzCja+d0iPaLnwNn5Uk19feVEzaptO8cAS4Katw2ECyoz/jRRrlNXquQhMdftdx3yJsibqUJHfxp5iyO/+7seGBuAeXWgg3lakd34929Ce9hC1X96+LnpvRIg6/D8KL/l02bAmftT1tNOcAky7ZzH8IlUPSyoJbKzVPbCNHDR/Cv/QwCi1IuKkez/e4yeOmXyO/DD1/3tNec44x75615P4zovB3C7/zhd+flYwZiE5F6DX8Sw9KaP0GPD/AHb8uftE8fFJmxwnnmX3bQuG1O0OQn34F+GEAdd1xd3auEtkxfJC/8/lTXPj9GY/zuKlmuob8vtoHW3PnjOjC0WsDWsGhZ2p0qNHh9zI857baHNG+SsdwC0a4owbP/OFWj5s8blrhdXfVE/5bl/bQ2ynkb5TGI3TwHj/c2oSXmBIuITuGD76nC60W4o6heGmPm9YpOQaNcfh9qH+L8iaz8K5vykeuUnWdTrSXQ8/yt41fiXHTDXf/xX3PeNxf3LeHwiPRmJKRtfYKR8QHp/eEQxZ5Rbs4/K6D9/Doldqr0HSH33+4dRxed0uFJ6QxJSNr7RsdH5kxxxu41CvVvWhl2sKhxnL3WdQiuNU6vm3BfWVMyeAqm8Z6+D2dK9I/3KRDb4tw5aotwokOvTr0TI1O+GyYv3rRTWVk4fhyOwZaLjn+tsHKEWofSGNZWtOhZ2rMk/Hy7NCrQ8/U6FCjbXTNwsv6qFSML7dXrMPrDb/qkyu0D3hEqyGLhGTBwmVlmJ+XmBK2JwfYQ9csv2zt+EIbxdrdTa43/J4N6DyEm8qE4xumZ8hqr2uGI+khSXozYyxpuKxSfHYJd3gx9zz8nj3oPA6/V+qZe0erOfyeIr35YcQvNux4O5ObVt23YUqJ7SJ+xWbLPKCDhbijQO34JFpEcOuNdIVj/IwE7v4AuW/trdtmvfpQ6Me6PqPH7wWqBhPagkQt9BqRrnBA+Bzxwx97LaFrNtyXphBuGuETQVfF36TsqxSOpGGEmwLJRkJd8peEz841LpBsNEYu2HzT4SEyHvGxrgz9kZawnRodfm/Fqzx4GkBzCTel3Afkx59ObufvXX1TmtIwMc9yxPX4Lxh/Tnog1KXkaYundkEDHHmmdid8tkTu5a/bckea1TY3w2a4zUvmgTTms8T1hqSRHswIb+c0X5AmNk9/Yi3cH3Hl1N9UkJao/QmNJ/RK7TbIvUjz7Wgdwk2DmAr3p0SpQMnh8HsBGhz+tSG6S8/V9IJjJ9xf47IhTIjotRBNCeeGz8e5H/7eUoXm9qzw5NQQgxMmxJVf9flBU8K58nCc8Bbk3lJFpvcs8uTUKAORnPBJcqHXQjL+/nCQ69q3Yycbq8j0znWSzosyhHx2XR8x/FtOxt8fjuBOmzzwU3s5WaFznScnRRmSwhShh3Iy/v6wueuqHr//JBsbyCJDVrs7I8qQ55ONcVMZmSIT5WFb/sgXfg88tdcK1xmy4N3uUYZClCsOv5eRKTJRHjbkD3vh978yXbXCdUatGdk3ylCrLUVolsxVyrMe7kiE32/yvbWi1QauHNouytAsyphCNEUmNqyg5LrMDzelvA6oFa02dnGxS5Shn8/Aug8qU2SiPKziT8S46UHJmAbRmhpbOIujDAP5PKz+oDRFJjasMMR19B9uesbjFI56X1NjF2dNlEGDT8XqD0pTZKJfY1JW0F6Em97waJ0TJlfW2ov/hWNRughuLUZTwokNi7y6TnbDfWV4jsLZRHJxpR0Vr2GD6pfuceXgT9hCz+VoSjiXnu+o9467C/CESjK3eYVC9/X9ziqb6t4EhqNUcPg98NSeJ1PuD+JatwCPHoQX9aSFHpTc1/ebq2yqexMYhTLA4fcU6s2PiYSD5dk9hO2T0e6Em7zodbjk+nqbLosvFLoSsOzzy7Da8eTapnKFgWh3wk2Bp/aBnvblp9FmxxcK+Uy78HsBGS8PT54GSHuydzjaTnBrSr6339P6evvOiC/kXUl3w301olm0DoleHRpzx90/3DoCr/gX92WVj2z2tL7evrr3gQyfToyb+jytQ+1+n6KNZCQ9jEVbVGmbVe7pYE/tQ+heCZKUvujANQuX8ve4RhaObyBb6HlaX3Vr3StBRO9bjl1Z6ZC1xl4qKbO+6u5bxPcj9L6iM3Zxn3LpBTNdw2lvlLkLdTn8PtqkCH7c8E84fMG7p/Vpa8GtClQXJ5ktqEvvDOp3A/fxhn8/WjPEHeNk1qQdk3hEt7GrJeXXp169M+jeDZS+nFs2j8d1yCxCW7zi0fU6p5d43YJ682N66F7PAP+BYtz3jMfpfbZKPK1GZhatWYsnF6ga3Ca/hT/vNSA/rIf6Da2ib5PB43TwHqPRyrQFofZCmfG0Womqwc3yu0iv3mFmXNI893n0vlAS7bhK1RlocKHa8W1ed5EBeueZcU+r3Fch/D4Rb7yHzHnotIVqx7cpORgNKBnZbMZVjaHv4fD7CnyCvfFZyzRMafO6i5xEHjTMuKoZ9CUcfl+Hz7ExPmixhiltXjfyx7/GyIOGSbc9Gn0Ah983wAfaFZ+yWNusNq8byWFeR/aYdNudUaDzeOg2+Fhb4iMWa5vV7HUvGaB6qnkXnuD6gCPwchvjgy6SOQN1VWmb1abkkDLgdWSPeXeeyYf3D+6wgm81EW8c4I4fbq3UM1eJnEf1YHvduY3/djHu+wa+8zi8bhYP9bipXs9cJXIk1bNtd+2M6ws/4BEwSElUaYzD75V65qqiU2kfb8ebO3TtO+6GFAmRPCRRr8PvKa8DnJIxT3rmaqODaZ9w/eXphnfcDcXCuNEzoRYnes0rH1mr6hjz0dm0D7nm/nQrwa3Q7R7MsMUHOxHt8sZ+/ggqK49Cx9M+5KQQ+Gj/wR0wVG1gM98i09Vm+IJK6JwOv+vQWp3PHuAO0FQV59fvUrVa3ute+6Bzap92cGRD3AETlYe9ZKT/jL3fccgi82mfuWV1CuUdd8M68hXuX4RaQtzxrHBYRv8Kq2gfO7c6Re0JD4KdRN8lfPUfrfqrNUwRbTtuQvvk8Ye54244gcb3ojRwotekcAw9H4dOrn3+f6ufGykgV7LrfERaOcQdN/neI9D5tS9ydowgpJorJYvTGIffz0Tn177I2TGCkHquZBfX3n0auoX2XSxECojP/DUfdOHWY8lF5EEJCs8O7Vx5smRTPXQdH0sUHhTQzpW7+TtOo301FJ4d2rkSmblXJH/TIQfLb9FvWexgOO1cCU3bKCm5OzV2Hkymu4fOpfIUl4b5VHNFzNnlSXL3q0o8fm8SrhA+a1gZQRhLO1fIhC3K0WH8vQecKlxk1JpPNgoidNLOFWfCFhmyOz0I6u0XLjV25btlQQQNurminIslVM8Qrqy6kbM4jjCWXq6oZuErXwW6B4i2UN+O/4XzRakzitKyVSacIVx/xnb8L5xvbLrQUmPXbDP/ABN2XBxTGGhgulzVtrreZgovO+fiKDw7jJXKVfpzauDvLpM25X/hfHMyxph71c0JIz6VHXMyZhrt6/gSi7fQ3lSg8IxIptG5tO+SDJf2piEUnhEzk+Z0vugSVXdv1IOvZcTMpDlaMlC+6KYGEF/LiMl5o0rvLr6+4sWTjdpQeEbMT53jJAtsVdzwtYxYlUAH2afqHHwtC1wCLcyhU4QhWh4xfC0LlqfR/sL47BAufC0LlqfR5sL4+KJbHy58MAsok3bIpw2FYblqbo8o4VNZQMm0SUptJYzJVXPbhAifygLKp32yahNRQLaKDz6VBSi8OxeNMCC7BQefygLJqt3Sa5Wr5v5WXfi6A3wnCySrdkuvVaI4bBgWfCcLXGJJbm2YZJNFEdgzICg8C66yC9Jrz1SbI7r7tqFA4Rnx5WIT96rbNiz4WkaEGbZzwk2zeRBQeEag0iKbBwRfywj/3/c/X/Pe8h37XxyFZ0cy23z12f/K4R2PuDIKz479s01JWGnh885QeHacknN6DooACs8UFB4/bQ+FZ8qXC++su6PwTPls4R13cRSeKS7/Plh7J94ahWfN1wrvxKpzUHjWfKrwDq06B4Vnzbm5WOvom6LwDPpO4fHTgVB4Bn2h8E6/IwrPIPOF5y6IwoPtfKHw+OlYKDyDbBeejduh8AwyXHjuaig82JTtwuOnw6HwDLJaeJbuhcIzyGThuUuh8GBrVguPn0xA4Rlkr/AM3oj/BStcjhpLU3s3clB41thLU3tV56DwTKEctZSp139FUHiwOcpRS5lqsuocFJ4d10+DrcIzc5E7FJ4dkqY28tXdwsZFklB4RkiaysPpbNziCQrPCElTVN0RUHgWuDSVTDWQsuF1rELhWRCmqYGUNV91DgrveNevg6HCi65jFQrveFGanp61X6g6B4V3PEuZ+pGqc1B4Z7P0c+cOf/T5q6DwzhZl6tGJ+52qc1B4B7t+IKwk66eqzkHhHeyerOemLwoPjoGfu3Oh8A5mI18/WHUOCu9ULl+jlD0xg++3+AgU3qnu+XpiBn+z6hwU3qkMFJ478HFnHgWFdyQbKfvZqnNQeEeykbIoPDiMjZ87FB4cxkbh8dMnofDOYyNlUXhwGBs/dyg8OImNfP141TkovMOg8GxA4Z3E5auBlLVxi04ovJPYyFdUnYMQHMNMvqLwHITgDC5ZbeSrmYt0QgjOYCZZUXUEUTiApWRF4RFEYXcuU80kq6W7dEIUdmcpU1F1AoHYmv+FMFV4lq7TA1HYmrE0ReEJRGFfJnMUhUcQhU353wZrX8fkpdogCpsymaAoPIEo7MhwgqLwCKKwI8PZicIjiMJ2bKcmCo8gCntxeYnC+wJEYS/mqw6FRxCFjZjPS1SdQCA2Yj4vUXgCgdjFF5IShScQiC24jDSflF+4YzkEYgtfyEhUXQixWO8jVYfCCyEWi30kI1F1EYRjsY9UHQovgnCs9JF0RNXdISLL+J8B+/FH1SUhKMt8pOpQeEkIyhofSUdU3RPEZQH/M2A/8qi6DIRmgY9UHQovA6GZ7SPpiKrLQ3Sm8j8D9mP+kWv2QHSm+kg6oupeIUDzoOpAIEaTuHRE4YFAjGZA1UEEYZrhO+mIwiuEMKm7fuzwcwd/IVLqvpOOKLxyiJSuT1UdCq8cIqXoU7mIqquCYCn6VNWh8KogWFo+lYuoulqIl5ZP5SIKrxbipeJrVYfCq4V4jfe1RETVNUDIxvta1aHwGiBkg30tC1F1bRC1kfx//VF48A5RGwZVB+UQOGiHwmuGwEE7FF4zBA4aXf9jjcJrhcBBI1RdD8QOGqHweiB20AiF1wOxgxaouk4IH7RA4XVC+KAFCq8TwgfVUHX9EEGohsLrhwhCNRReP0QQ6qDqhkAQoQ4KbwgEESqg6kZBHKECCm8UxBFKoeoGQiihFApvIIQSSqHwBkIooQiqbixEE4qg8MZCNKEICm8sRBPeuapD4Y2FaMI7VN1wCCi8Q+ENh4DCC1SdBsQUXqDwNCCm8AKFpwExhRxUnRKEFXJQeEoQVniEqtODyMIjFJ4eRBbSXNWh8PQgspCGqlOF4EIaCk8VggsJqDptiC8koPC0Ib4QQ9VNgBBDDIU3AUIMsAAKD2ABFB7AAig8gAVQeAALoPAAFkDhASyAwgNYAIUHsAAKD2C6//77P4kR71n3MSGlAAAAAElFTkSuQmCC" /></p><p>&nbsp;</p><p>2- التزليق.</p><p>أمسك جهاز ديسكير وقطعة الفم متّجهة نحوك. زلق الذراع بعيداً عنك لأقصى حد ممكن&ndash; إلى أن تسمع صوت طقطقة. جهاز ديسكير أصبح الآن جاهزاً للاستخدام. كل مرة تندفع الذراع للخلف، تنفتح فقاعة وتصبح الجرعة جاهزة للاستنشاق. وهذا يبينه عداد الجرعات. لا تعبث بالذراع فهذا يطلق جرعات تضيع سدى.</p><p><img alt="" width="305" height="350" src="data:image/png;base64,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" /></p><p>3-الاستنشاق.</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; قبل البدء باستنشاق الجرعة، اقرأ هذا القسم بعناية.</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; أمسك جهاز ديسكير بعيداً عن فمك. أطلق الزفيربقدر المستطاع دون مضايقة. تذكّر- لا تنفخ أبداً داخل جهاز ديسكير.</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; ضع قطعة الفم بين شفتيك. خذ نفساً مطرداً و عميقاً &ndash; من خلال جهاز ديسكير، وليس من خلال أنفك.</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; أخرج جهاز ديسكير من فمك.</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إحبس نفسك لمدة 10 ثوانٍ تقريباً، أو طالما ذلك لا يسبب أي مضايقة.</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; أطلق الزفير ببطء.</p><p><img alt="" width="295" height="314" src="data:image/png;base64,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" /></p><p>&nbsp;</p><p>4-الغلق.</p><p>لغلق جهاز ديسكير، ضع إبهامك في مقبض الإبهام، وزلق مقبض الإبهام نحوك لأقصى حدممكن.</p><p>عندما تغلق جهاز ديسكير، ستسمع صوت طقطقة تدل على إغلاقه. ستعود الذراع تلقائياً لوضعها الأصلي ويعاد ضبط الجهاز. جهاز ديسكير أصبح الآن جاهزاً للاستخدام مرة أخرى.</p><p><img alt="" width="295" height="286" src="data:image/png;base64,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" /></p><p>5-المضمضة</p><p>بعد ذلك، يتم مضمضة الفم بالماء ويبصق للخارج.</p><p>&nbsp;</p><p>إذا أوصيت باستنشاق محتوي فقاعتين، يجب أن تغلق جهاز ديسكير وتكرر الخطوات من 1 إلى 4 .</p><p><strong>تذكّر</strong></p><p>حافظ على جهاز ديسكير جافاً.</p><p>احتفظ بجهاز ديسكير مغلقاً في حالة عدم استخدامه.</p><p>لا تنفخ أبداً داخل جهاز ديسكير.</p><p>لا تزلق الذراع إلا وأنت مستعد لتناول جرعة.</p><p>لا تتجاوز الجرعة المقررة.</p><p>&nbsp;</p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ShapeAndContentsAr">ب‌. كيف يبدو شكل هذا المستحضر وماهي محتويات العلبة</label>
        </div>
        <div class="m-r-60">
            <p>جهاز بلاستيكي مقولب يحتوي على شريط فضي من 28 أو 60 فقاعة موضوعة بانتظام وتحتوي كل منها على مسحوق للإستنشاق لجرعة واحدة. لا تتوفر جميع أشكال العبوات في كل بلد.</p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ManufacturingAndMarketingAr">ت‌. الشركة المصنعة ومالك حق التسويق</label>
        </div>
        <div class="m-r-60">
            <p><strong>تصنيع:</strong></p><p>جلاكسو أوبيريشنز المملكة المتحدة المحدودة، وير، المملكة المتحدة</p><p>جلاكسو ويلكم برودكشن ، ايفرويكس ، فرنسا</p><p>&nbsp;</p><p><strong>تعبئة:</strong></p><p>جلاكسو السعودية العربية المحدودة، جدة، السعودية</p><p>*عضو في مجموعة شركات جلاكسو سميث كلاين</p><p><strong>&nbsp;</strong></p><p><strong>لصالح</strong></p><p>الدوائية</p><p>مصنع الأدوية بالقصيم</p><p>المملكة العربية السعودية</p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="RevisionNoteAr">ث‌. تمت مراجعة هذه النشرة في التاريخ الذي تمت فيه مراجعة النشرة بالشهر والسنة</label>
        </div>
        <div class="m-r-60">
            28 فبراير 2019
        </div>
    </div>
</div>
    </div>
    <div id="M-div" class="box-data">


    <div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue font-15 m-t-20 m-b-20 ltr"><i class="fa fa-info-circle"></i>&nbsp;Read this leaflet carefully before you start using this product as it contains important information for you</div>
    </div>
<div class="row clearfix ltr">

    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="MedicinalName">1. NAME OF THE MEDICINAL PRODUCT </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Respira Evohaler 50µg/250 µg per Inhalationdose,inhalation powder.
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="QualitativeQuantitativeComposition">2. QUALITATIVE AND QUANTITATIVE COMPOSITION </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Moulded plastic device containing a foil strip with 28 or 60 regularly placed blisters each containing 50 micrograms of salmeterol as salmeterol xinafoate and 250 micrograms of fluticasone propionate.
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="DosageForm">3. PHARMACEUTICAL FORM </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Inhalation powder.
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">4. CLINICAL PARTICULARS</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="TherapeuticIndications">4.1 Therapeutic Indications</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><strong>Asthma (Reversible Obstructive Airways Disease)</strong></p><p><em>Respira</em>is indicated in the regular treatment of asthma where use of a combinationproduct (long-acting beta-2-agonist and inhaled corticosteroid) is appropriate:</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Patients who are symptomatic on current inhaled corticosteroid therapy</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Patients already adequately controlled on both inhaled corticosteroid and longactingbeta-2-agonist.</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Patients on regular bronchodilator therapy who require inhaled corticosteroids.</p><p>&nbsp;</p><p><strong>Chronic Obstructive Pulmonary Disease (COPD)</strong></p><p><em>Respira</em> is indicated for the regular treatment of chronic obstructive pulmonary disease (COPD) including chronic bronchitis and emphysema.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PosologyAndMethodAdministration">4.2 Posology And Method Administration</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><em>Respira</em> Accuhaler/Diskair is for inhalation only.</p><p>Patients should be made aware that <em>Respira</em> Accuhaler/Diskair must be used regularly for optimum benefit, even when asymptomatic.</p><p>Patients should be regularly reassessed by a doctor, so that the strength of <em>Respira</em> they are receiving remains optimal&nbsp; and is only changed on medical advice.</p><p><strong>Asthma (Reversible Obstructive Airways Disease)</strong></p><p>The dose should be titrated to the lowest dose at which effective control of symptoms is maintained.&nbsp; Where the control of symptoms is maintained with twice daily <em>Respira</em>, titration to the lowest effective dose could include <em>Respira</em> given once daily.</p><p>Patients should be given the strength of <em>Respira</em> containing the appropriate fluticasone propionate dosage for the severity of their disease.</p><p>If a patient is inadequately controlled on inhaled corticosteroid therapy alone, substitution with RESPIRA at a therapeutically equivalent corticosteroid dose may result in an improvement in asthma control. For patients whose asthma control is acceptable on inhaled corticosteroid therapy alone, substitution with RESPIRA may permit a reduction in corticosteroid dose while maintaining asthma control. For further information, please refer to the &lsquo;Pharmacodynamics&rsquo; section.</p><p><strong>Recommended Doses:-</strong></p><p><strong>Adults and adolescents 12 years and older:-</strong></p><p>One inhalation (50 micrograms salmeterol and 100 micrograms fluticasone propionate) twice daily.</p><p>or</p><p>One inhalation (50 micrograms salmeterol and 250 micrograms fluticasone propionate) twice daily.</p><p>or</p><p>One inhalation (50 micrograms salmeterol and 500 micrograms fluticasone propionate) twice daily.</p><p><strong>Children 4 years and older:-</strong></p><p>One inhalation (50 micrograms salmeterol and 100 micrograms fluticasone propionate) twice daily.</p><p>There are no data available for use of <em>Respira</em> in children aged under 4 years.<br />&nbsp;</p><p><strong>Chronic Obstructive Pulmonary Disease (COPD)</strong></p><p>For adult patients the recommended dose is one inhalation 50/250 micrograms to 50/500 micrograms salmeterol/fluticasone propionate twice daily. At a dose of 50/500 micrograms twice daily, <em>RESPIRA</em> has been shown to reduce all-cause mortality (<em>see Clinical Studie</em>s).</p><p><strong>Special patient groups:-</strong></p><p>There is no need to adjust the dose in elderly patients or in those with renal or hepatic impairment.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Contraindications">4.3 Contraindications</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                RESPIRA is contraindicated in patients with a history of hypersensitivity to any of the ingredients (see List of Excipients).
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="SpecialWarnings">4.4. Special warnings and precautions for use</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><em>Respira</em>Accuhaler/Diskair is not for relief of acute symptoms for which a fast and short-acting bronchodilator (e.g. salbutamol) is required.&nbsp; Patients should be advised to have their relief medication available at all times.</p><p>Increasing use of short-acting bronchodilators to relieve symptoms indicates deterioration of control and patients should be reviewed by a physician.</p><p>Sudden and progressive deterioration in control of asthma is potentially life-threatening and the patient should be reviewed by a physician.&nbsp; Consideration should be given to increasing corticosteroid therapy.&nbsp; Also, where the current dosage of <em>Respira</em> has failed to give adequate control of asthma, the patient should be reviewed by a physician.</p><p>&nbsp;</p><p>Treatment with <em>Respira</em> should not be stopped abruptly in patients with asthma due to risk of exacerbation, therapy should be titrated-down under physician supervision.&nbsp; For patients with COPD cessation of therapy may be associated with symptomatic decompensation and should be supervised by a physician.</p><p>There was an increased reporting of pneumonia in studies of patients with COPD receiving <em>RESPIRA</em> (<em>see Adverse Reactions</em>).&nbsp; Physicians should remain vigilant for the possible development of pneumonia in patients with COPD as the clinical features of pneumonia and exacerbation frequently overlap.</p><p>As with all inhaled medication containing corticosteroids, <em>Respira</em> should be administered with caution in patients with active or quiescent pulmonary tuberculosis.</p><p><em>Respira</em> should be administered with caution in patients with thyrotoxicosis.</p><p>Cardiovascular effects, such as increases in systolic blood pressure and heart rate, may occasionally be seen with all sympathomimetic drugs, especially at higher than therapeutic doses. For this reason, <em>RESPIRA</em> should be used with caution in patients with pre-existing cardiovascular disease.</p><p>A transient decrease in serum potassium may occur with all sympathomimetic drugs at higher therapeutic doses. Therefore, <em>RESPIRA</em> should be used with caution in patients predisposed to low levels of serum potassium.</p><p>Systemic effects may occur with any inhaled corticosteroid, particularly at high doses prescribed for long periods; these effects are much less likely to occur than with oral corticosteroids (<em>see Overdose</em>).&nbsp; Possible systemic effects include Cushing&rsquo;s syndrome, Cushingoid features, adrenal suppression, growth retardation in children and adolescents, decrease in bone mineral density, cataract and glaucoma.&nbsp; It is important, therefore asthmapatients, that the dose of inhaled corticosteroid is titrated to the lowest dose at which effective control is maintained.</p><p>The possibility of impaired adrenal response should always be borne in mind in emergency and elective situations likely to produce stress and appropriate corticosteroid treatment considered (<em>see Overdose</em>).</p><p>It is recommended that the height of children receiving prolonged treatment with inhaled corticosteroid is regularly monitored.</p><p>Because of the possibility of impaired adrenal response, patients transferring from oral steroid therapy to inhaled fluticasone propionate therapy should be treated with special care, and adrenocortical function regularly monitored.</p><p>Following introduction of inhaled fluticasone propionate, withdrawal of systemic therapy should be gradual and patients encouraged to carry a steroid warning card indicating the possible need for additional therapy in times of stress.</p><p>There have been very rare reports of increases in blood glucose levels (<em>see Adverse Reactions</em>) and this should be considered when prescribing to patients with a history of diabetes mellitus.</p><p>During post-marketing use, there have been reports of clinically significant drug interactions in patients receiving fluticasone propionate and ritonavir, resulting in systemic corticosteroid effects including Cushing&rsquo;s syndrome and adrenal suppression.&nbsp; Therefore, concomitant use of fluticasone propionate and ritonavir should be avoided, unless the potential benefit to the patient outweighs the risk of systemic corticosteroid side-effects<em>(see Interactions)</em>.</p><p>It was observed in a drug interaction study that concomitant use of systemic ketoconazole increases exposure to <em>SEREVENT</em>. This may lead to prolongation in the QTc interval. Caution should be exercised when strong CYP3A4 inhibitors (e.g. ketoconazole) are co-administered with <em>SEREVENT</em>. (<em>see Interactions, and Pharmacokinetics</em>).</p><p>As with other inhalation therapy paradoxical bronchospasm may occur with an immediate increase in wheezing after dosing.&nbsp; This should be treated immediately with a fast and short-acting inhaled bronchodilator.&nbsp; Salmeterol-FP Accuhaler/Diskair or Evohaler should be discontinued immediately, the patient assessed and alternative therapy instituted if necessary.(<em>see Adverse Reactions</em>)</p><p>The pharmacological side-effects of beta-2 agonist treatment, such as tremor, subjective palpitations and headache have been reported, but tend to be transient and to reduce with regular therapy. (<em>see Adverse Reactions</em>)</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="InteractionsOtherMedicines">4.5. Interactions with other medicinal products</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Both non-selective and selective beta-blockers should be avoided unless there are compelling reasons for their use.</p><p>Under normal circumstances, low plasma concentrations of fluticasone propionate are achieved after inhaled dosing, due to extensive first pass metabolism and high systemic clearance mediated by cytochrome P450 3A4 in the gut and liver.&nbsp; Hence, clinically significant drug interactions mediated by fluticasone propionate are unlikely.</p><p>A drug interaction study in healthy subjects has shown that ritonavir (a highly potent cytochrome P450 3A4 inhibitor) can greatly increase fluticasone propionate plasma concentrations, resulting in markedly reduced serum cortisol concentrations.&nbsp; During post-marketing use, there have been reports of clinically significant drug interactions in patients receiving intranasal or inhaled fluticasone propionate and ritonavir, resulting in systemic corticosteroid effects including Cushing&rsquo;s syndrome and adrenal suppression.&nbsp; Therefore, concomitant use of fluticasone propionate and ritonavir should be avoided, unless the potential benefit to the patient outweighs the risk of systemic corticosteroid side-effects.</p><p>Studies have shown that other inhibitors of cytochrome P450 3A4 produce negligible (erythromycin) and minor (ketoconazole) increases in systemic exposure to fluticasone propionate without notable reductions in serum cortisol concentrations.&nbsp; Nevertheless, care is advised when co-administering potent cytochrome P450 3A4 inhibitors (e.g. ketoconazole) as there is potential for increased systemic exposure to fluticasone propionate.</p><p>Co-administration of ketoconazole and <em>SEREVENT</em> resulted in a significant increase in plasma salmeterol exposure (1.4-fold C<sub>max</sub> and 15-fold AUC) and this may cause a prolongation of the QTc interval. (<em>see Warnings and Precautions, and Pharmacokinetics</em>)</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="FertilityAndPregnantWarnings">4.6. Fertility, pregnancy and lactation</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>There are no data on human fertility.&nbsp; Animal studies indicate no effects of fluticasone propionate or salmeterol xinafoate on male or female fertility.</p><p><em>Pregnancy Category C:</em>There are limited data in pregnant women. Administration of drugs during pregnancy should only be considered if the expected benefit to the mother is greater than any possible risk to the foetus or child.</p><p>Reproductive toxicity studies in animals, either with single drug or in combination, revealed the foetal effects expected at excessive systemic exposure levels of a potent beta<sub>2</sub>-adrenoreceptor agonist and glucocorticosteroid.</p><p>Extensive clinical experience with drugs in these classes has revealed no evidence that the effects are relevant at therapeutic doses.</p><p>Salmeterol and fluticasone propionate concentrations in plasma after inhaled therapeutic doses are very low and therefore concentrations in human breast milk are likely to be correspondingly low.&nbsp; This is supported by studies in lactating animals, in which low drug concentrations were measured in milk.&nbsp; There are no data available for human breast milk.</p><p>A risk to breastfed newborns/infants cannot be excluded. A decision must be made whether to discontinue breastfeeding or to discontinue Respira therapy taking into account the benefit of breastfeeding for the child and the benefit of therapy for the woman.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="EffectsAbilityDriveMachines">4.7. Effects on ability to drive and use machines</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>There have been no specific studies of the effect of <em>Respira</em> on the above activities, but the pharmacology of both drugs does not indicate any effect.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="UndesirableEffects">4.8. Undesirable effects</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>All of the adverse reactions associated with the individual components, salmeterol xinafoate and fluticasone propionate, are listed below.&nbsp; There are no additional adverse reactions attributed to the combination product when compared to the adverse event profiles of the individual components.</p><p>Adverse events are listed below by system organ class and frequency.&nbsp; Frequencies are defined as: very common (&ge; 1/10), common (&ge;1/100 to &lt;1/10), uncommon (&ge;1/1000 to &lt;1/100), rare (&ge;1/10,000 to &lt;1/1000) and very rare (&lt;1/10,000).&nbsp; The majority of frequencies were determined from pooled clinical trial data from 23 asthma and 7 COPD studies.&nbsp; Not all events were reported in clinical trials.&nbsp; For these events, the frequency was calculated based on spontaneous data.</p><p>Clinical Trial Data</p><p><strong>Infections and infestations</strong></p><p>Common:&nbsp; Candidiasis of mouth and throat, pneumonia (in COPD patients).</p><p>Rare:&nbsp;&nbsp;&nbsp; Oesophageal candidiasis</p><p><strong>Immune system disorders</strong></p><p>Hypersensitivity Reactions:</p><p>Uncommon:&nbsp; Cutaneous hypersensitivity reactions, dyspnoea.</p><p>Rare:&nbsp; Anaphylactic reactions</p><p><strong>Endocrine disorders</strong></p><p>Possible systemic effects include (see Warnings and Precautions):</p><p>Uncommon:&nbsp; Cataract</p><p>Rare:&nbsp; Glaucoma</p><p><strong>Metabolism and nutrition disorders</strong></p><p>Uncommon:&nbsp; Hyperglycaemia.</p><p><strong>Psychiatric disorders</strong></p><p>Uncommon: &nbsp;Anxiety, sleep disorders.</p><p>Rare:&nbsp; Behavioural changes, including hyperactivity and irritability (predominantly in children).</p><p><strong>Nervous system disorders</strong></p><p>Very common:&nbsp; Headache (see Warnings and Precautions).</p><p>Uncommon:&nbsp; Tremor (see Warnings and Precautions).</p><p><strong>Cardiac disorders</strong></p><p>Uncommon:&nbsp; Palpitations (see Warnings and Precautions), tachycardia, atrial fibrillation.</p><p>Rare: Cardiac arrhythmias including supraventricular tachycardia and extrasystoles.</p><p><strong>Respiratory, thoracic and mediastinal disorders</strong></p><p>Common:&nbsp; Hoarseness/dysphonia.</p><p>Uncommon:&nbsp; Throat irritation.</p><p><strong>Skin and subcutaneous tissue disorders</strong></p><p>Uncommon: Contusions.</p><p><strong>Musculoskeletal and connective tissue disorders</strong></p><p>Common:&nbsp; Muscle cramps, arthralgia.</p><p>Postmarketing Data</p><p><strong>Immune system disorders</strong></p><p>Hypersensitivity reactions manifesting as:</p><p>Rare:&nbsp; Angioedema (mainly facial and oropharyngeal oedema) and bronchospasm.</p><p><strong>Endocrine disorders</strong></p><p>Possible systemic effects include (see Warnings and Precautions):</p><p>Rare:&nbsp; Cushing&rsquo;s syndrome, Cushingoid features, adrenal suppression, growth retardation in children and adolescents, decreased bone mineral density.</p><p><strong>Respiratory, thoracic and mediastinal disorders</strong></p><p>Rare:&nbsp; Paradoxical bronchospasm (see Warnings and Precautions)</p><p><strong>To report any side effect(s):</strong></p><p><strong>&nbsp;</strong></p><p><strong><em>Kingdom of Saudi Arabia</em></strong></p><p><strong>-National Pharmacovigilance centre (NPC)</strong></p><ul><li>Fax: +966-11-205-7662</li><li>Call NPC at +966-11-2038222, Ext: 2317-2356-2353-2354-2334-2340</li><li>Toll-free: 8002490000</li><li>E-mail: npc.drug@sfda.gov.sa</li><li>Website: www.sfda.gov.sa/npc</li></ul><p>&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Overdoes">4.9. Overdoes</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>The available information on overdose with <em>Respira</em>, salmeterol and/or fluticasone propionate is given below:</p><p>The expected symptoms and signs of salmeterol overdosage are those typical of excessive beta2&ndash;adrenergic stimulation, including tremor, headache, tachycardia, increases insystolic blood pressure and hypokalaemia. There is no specific treatment for an overdose of salmeterol and fluticasone propionate. If overdose occurs, the patient should be treated supportively with appropriate monitoring as necessary.</p><p>Acute inhalation of fluticasone propionate doses in excess of those approved may lead to temporary suppression of the hypothalamic-pituitary-adrenal axis.&nbsp; This does not usually require emergency action as normal adrenal function typically recovers within a few days.</p><p>If higher than approved doses of <em>Respira</em> are continued over prolonged periods, significant adrenocortical suppression is possible.&nbsp; There have been very rare reports of acute adrenal crisis, mainly occurring in children exposed to higher than approved doses over prolonged periods (several months or years); observed features have included hypoglycaemia associated with decreased consciousness and/or convulsions. &nbsp;Situations which could potentially trigger acute adrenal crisis include exposure to trauma, surgery, infection or any rapid reduction in the dosage of the inhaled fluticasone propionate component.</p><p>It is not recommended that patients receive higher than approved doses of <em>Respira</em>.&nbsp; It is important to review therapy regularly and titrate down to the lowest approved dose at which effective control of disease is maintained (<em>see Dosage and Administration</em>).</p>
            </div>
        </div>
    </div>

    <div class="col-xs-12">
        <label style="float: left">5. PHARMACOLOGICAL PROPERTIES</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PharmacodynamicProperties">5.1. Pharmacodynamic Properties</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><strong>Asthma</strong></p><p><strong>Salmeterol Multi-center Asthma Research Trial (SMART)</strong></p><p>The Salmeterol Multi-center Asthma Research Trial (SMART) was a 28-week US study that evaluated the safety of salmeterol compared to placebo added to usual therapy in adult and adolescent subjects. Although there were no significant differences in the primary endpoint of the combined number of respiratory-related deaths and respiratory-related life-threatening experiences, the study showed a significant increase in asthma-related deaths in patients receiving salmeterol (13 deaths out of 13,176 patients treated&nbsp; with salmeterol versus 3 deaths out of 13,179 patients on placebo). The study was not designed to assess the impact of concurrent inhaled corticosteroid use.&nbsp;</p><p>&nbsp;</p><p><strong>Safety and efficacy of salmeterol-FP versus FP alone in asthma</strong></p><p>&nbsp;Two multi-centre 26-week studies were conducted to compare the safety and efficacy of salmeterol-FP versus FP alone, one in adult and adolescent subjects (AUSTRI trial), and the other in paediatric subjects 4-11 years of age (VESTRI trial). For both studies, enrolled subjects had moderate to severe persistent asthma with history of asthma-related hospitalisation or asthma exacerbation in the previous year. The primary objective of each study was to determine whether the addition of LABA to ICS therapy (salmeterol-FP) was non-inferior to ICS (FP) alone in terms of the risk of serious asthma related events (asthma-related hospitalisation, endotracheal intubation, and death). A secondary efficacy objective of these studies was to evaluate whether ICS/LABA (salmeterol-FP) was superior to ICS therapy alone (FP) in terms of severe asthma exacerbation (defined as deterioration of asthma requiring the use of systemic corticosteroids for at least 3 days or an in-patient hospitalisation or emergency department visit due to asthma that required systemic corticosteroids).&nbsp;</p><p>A total of 11,679 and 6,208 subjects were randomized and received treatment in the AUSTRI and VESTRI trials, respectively. For the primary safety endpoint, non-inferiority was achieved for both trials (see Table below).</p><p>&nbsp;</p><p>Serious Asthma-Related Events in the 26-Week AUSTRI and VESTRI Trials</p><table border="1" cellspacing="0" cellpadding="0" style="width:635px"><tbody><tr><td rowspan="2" style="vertical-align:top"><p>&nbsp;</p></td><td colspan="2" style="vertical-align:top"><p>AUSTRI</p></td><td colspan="2" style="vertical-align:top"><p>VESTRI</p></td></tr><tr><td style="vertical-align:bottom"><p>Salmeterol-FP</p><p>(n = 5,834)</p></td><td style="vertical-align:bottom"><p>FP Alone</p><p>(n = 5,845)</p></td><td style="vertical-align:bottom"><p>Salmeterol-FP</p><p>(n = 3,107)</p></td><td style="vertical-align:bottom"><p>FP Alone</p><p>(n = 3,101)</p></td></tr><tr><td style="vertical-align:top"><p>Composite endpoint</p><p>(Asthma-related hospitalisation, endotracheal intubation,or death)</p></td><td style="vertical-align:top"><p>34 (0.6%)</p></td><td style="vertical-align:top"><p>33 (0.6%)</p></td><td style="vertical-align:top"><p>27 (0.9%)</p></td><td style="vertical-align:top"><p>21 (0.7%)</p></td></tr><tr><td style="vertical-align:top"><p>Salmeterol-FP/FP Hazard ratio (95% CI)</p></td><td style="vertical-align:top"><p>1.029</p><p>(0.638-1.662)<sup>a</sup></p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>1.285</p><p>(0.726-2.272)<sup>b</sup></p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>Death</p></td><td style="vertical-align:top"><p>0</p></td><td style="vertical-align:top"><p>0</p></td><td style="vertical-align:top"><p>0</p></td><td style="vertical-align:top"><p>0</p></td></tr><tr><td style="vertical-align:top"><p>Asthma-related hospitalisation</p></td><td style="vertical-align:top"><p>34</p></td><td style="vertical-align:top"><p>33</p></td><td style="vertical-align:top"><p>27</p></td><td style="vertical-align:top"><p>21</p></td></tr><tr><td style="vertical-align:top"><p>Endotracheal intubation</p></td><td style="vertical-align:top"><p>0</p></td><td style="vertical-align:top"><p>2</p></td><td style="vertical-align:top"><p>0</p></td><td style="vertical-align:top"><p>0</p></td></tr></tbody></table><p><sup>a</sup>&nbsp;&nbsp; If the resulting upper 95% CI estimate for the relative risk was less than 2.0, then non-inferiority was concluded.</p><p><sup>b</sup>&nbsp;&nbsp; If the resulting upper 95% CI estimate for the relative risk was less than 2.675, then non-inferiority was concluded.</p><p>For the secondary efficacy endpoint, reduction in time to first asthma exacerbation for salmeterol-FP relative to FP was seen in both studies, however only AUSTRI met statistical significance:</p><p>&nbsp;</p><table border="1" cellspacing="0" cellpadding="0" style="width:635px"><tbody><tr><td rowspan="2" style="vertical-align:top"><p>&nbsp;</p></td><td colspan="2" style="vertical-align:top"><p>AUSTRI</p></td><td colspan="2" style="vertical-align:top"><p>VESTRI</p></td></tr><tr><td style="vertical-align:bottom"><p>Salmeterol-FP</p><p>(n = 5,834)</p></td><td style="vertical-align:bottom"><p>FP Alone</p><p>(n = 5,845)</p></td><td style="vertical-align:bottom"><p>Salmeterol-FP</p><p>(n = 3,107)</p></td><td style="vertical-align:bottom"><p>FP Alone</p><p>(n = 3,101)</p></td></tr><tr><td style="vertical-align:top"><p>Number of subjects with an asthma exacerbation</p></td><td style="vertical-align:top"><p>480 (8%)</p></td><td style="vertical-align:top"><p>597 (10%)</p></td><td style="vertical-align:top"><p>265 (9%)</p></td><td style="vertical-align:top"><p>309 (10%)</p></td></tr><tr><td style="vertical-align:top"><p>Salmeterol-FP/FP Hazard ratio (95% CI)</p></td><td colspan="2" style="vertical-align:top"><p>0.787</p><p>(0.698, 0.888)</p></td><td colspan="2" style="vertical-align:top"><p>0.859</p><p>(0.729, 1.012)</p></td></tr></tbody></table><p>&nbsp;</p><p><strong>Twelve month study</strong></p><p>A large twelve-month study (Gaining Optimal Asthma ControL, GOAL) in 3416 asthma patients compared the efficacy and safety of <em>RESPIRA</em> versus inhaled corticosteroid alone in achieving pre-defined levels of asthma control. Treatment was stepped-up every 12 weeks until <sup>##</sup>&lsquo;Total control&rsquo; was achieved or the highest dose of study drug was reached. Control needed to be sustained for at least 7 out of the last 8 weeks of treatment. The study showed that:</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; 71% of patients treated with <em>RESPIRA</em> achieved <sup>#</sup>&lsquo;Well-controlled&rsquo; asthma compared with 59% of patients treated with inhaled corticosteroid alone.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; 41% of patients treated with <em>RESPIRA</em> achieved <sup>##</sup>&lsquo;Total control&rsquo; of asthma compared with 28% of patients treated with inhaled corticosteroid alone.</p><p>These effects were observed earlier with <em>RESPIRA</em> compared with inhaled corticosteroid alone and at a lower inhaled corticosteroid dose.</p><p>The GOAL study also showed that:</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; The rate of exacerbations was 29% lower with <em>RESPIRA</em> compared to inhaled corticosteroid treatment alone.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Attaining &lsquo;Well controlled&rsquo; and &lsquo;Totally controlled&rsquo; asthma improved Quality of Life (QoL). 61% of patients reported minimal or no impairment on QoL, as measured by an asthma specific quality of life questionnaire, after treatment with <em>RESPIRA</em> compared to 8% at baseline.</p><p>#Well controlled asthma; less than or equal to 2 days with symptom score greater than 1 (symptom score 1 defined as &lsquo;symptoms for one short period during the day&rsquo;), SABA use on less than or equal to 2 days and less than or equal to 4 occasions/week, greater than or equal to 80% predicted morning peak expiratory flow, no night-time awakenings, no exacerbations and no side effects enforcing a change in therapy.</p><p>##Total control of asthma; no symptoms, no SABA use, greater than or equal to 80% predicted morning peak expiratory flow, no night-time awakenings, no exacerbations and no side effects enforcing a change in therapy.</p><p>Two further studies have shown improvements in lung function, percentage of symptom free days and reduction in rescue medication use, at 60% lower inhaled corticosteroid dose with <em>RESPIRA</em> compared to treatment with inhaled corticosteroid alone, whilst the control of the underlying airway inflammation, measured by bronchial biopsy and bronchoalveolar lavage, was maintained.</p><p>Additional studies have shown that treatment with <em>RESPIRA</em> significantly improves asthma symptoms, lung function and reduces the use of rescue medication compared to treatment with the individual components alone and placebo.&nbsp; Results from GOAL show that the improvements seen with <em>RESPIRA</em>, in these endpoints, are maintained over at least 12 months.</p><p><strong>COPD</strong></p><p>Symptomatic COPD patients without restriction to 10% reversibility to a short acting beta<sub>2</sub><em>-</em>agonist:-</p><p>Placebo-controlled clinical trials, over 6 months, have shown that regular use of both <em>Respira</em> 50/250 and 50/500 micrograms rapidly and significantly improves lung function, significantly reduced breathlessness and the use of relief medication.&nbsp; There were also significant improvements in health status.</p><p>Symptomatic COPD patients who demonstrated less than 10% reversibility to a short acting beta<sub>2</sub><em>-</em>agonist:-</p><p>Placebo-controlled clinical trials, over 6 and 12 months, have shown that regular use of <em>Respira</em> 50/500 micrograms rapidly and significantly improves lung function, significantly reduced breathlessness and the use of relief medication.&nbsp; Over a 12-month period the risk of COPD exacerbations and the need for additional courses of oral corticosteroids was significantly reduced.&nbsp; There were also significant improvements in health status.&nbsp;</p><p><em>Respira</em> 50/500 micrograms was effective in improving lung function, health status and reducing the risk of COPD exacerbations, in both current and ex-smokers.</p><p><u>TORCH study (TOwards a Revolution in COPD Health):</u></p><p>TORCH was a 3-year study to assess the effect of treatment with <em>RESPIRA </em>Accuhaler/Diskair 50/500 micrograms twice daily, salmeterol Accuhaler/Diskair 50 micrograms twice daily, FP Accuhaler/Diskair 500 micrograms twice daily or placebo on all-cause mortality in patients with COPD. Patients with moderate to severe COPD with a baseline (pre‑bronchodilator) FEV<sub>1</sub>&lt;60% of predicted normal were randomised to double-blind medication. During the study, patients were permitted usual COPD therapy with the exception of other inhaled corticosteroids, long‑acting bronchodilators,and long-term systemic corticosteroids. Survival status at 3 years was determined for all patients regardless of withdrawal from study medication. The primary endpoint was reduction in all-cause mortality at 3 years for <em>RESPIRA</em> vs placebo.&nbsp;</p><table border="1" cellspacing="0" cellpadding="0"><tbody><tr><td><p>&nbsp;</p></td><td><p>Placebo</p><p>N = 1524</p></td><td><p>Salmeterol 50</p><p>N = 1521</p></td><td><p>FP 500</p><p>N = 1534</p></td><td><p><em>RESPIRA</em> 50/500</p><p>N = 1533</p></td></tr><tr><td colspan="5"><p>All cause mortality at 3 years</p></td></tr><tr><td><p>Number of deaths (%)</p></td><td><p>231</p><p>&nbsp;(15.2%)</p></td><td><p>205</p><p>&nbsp;(13.5%)</p></td><td><p>246</p><p>(16.0%)</p></td><td><p>193</p><p>(12.6%)</p></td></tr><tr><td><p>Hazard Ratio vs Placebo (CIs)<br />p value</p></td><td><p>N/A</p></td><td><p>0.879<br />(0.73, 1.06)<br />0.180</p></td><td><p>1.060<br />(0.89, 1.27)<br />0.525</p></td><td><p>0.825<br />(0.68, 1.00 )<br />0.052<sup>1</sup></p></td></tr><tr><td><p>Hazard Ratio <em>RESPIRA</em> 50/500 vs components (CIs)<br />p value</p></td><td><p>N/A</p></td><td><p>0.932<br />(0.77, 1.13)<br />0.481</p></td><td><p>0.774<br />(0.64, 0.93)<br />0.007</p></td><td><p>N/A</p></td></tr><tr><td colspan="5" style="vertical-align:top"><p>1. P value adjusted for 2 interim analyses on the primary efficacy comparison from a log-rank analysis stratified by smoking status<br />&nbsp;</p></td></tr></tbody></table><p><em>RESPIRA</em> reduced the risk of dying at any time during the 3 years by 17.5% compared to placebo (Hazard Ratio 0.825 (95% CI 0.68, 1.00, p=0.052; all adjusted for interim analyses). There was a 12% reduction in the risk of dying at any time within 3 years from any cause for salmeterol compared with placebo (p=0.180) and a 6% increase for FP compared with placebo (p=0.525).&nbsp;</p><p>A supporting analysis using Cox&#39;s Proportional Hazards model gave a hazard ratio of 0.811 (95% CI 0.670, 0.982, p=0.031) for <em>RESPIRA</em> vs placebo which represented a 19% reduction in the risk of dying at any time within 3 years.&nbsp; The model adjusted for important factors (smoking status, age, sex, region, baseline FEV<sub>1</sub> and Body Mass Index).&nbsp; There was no evidence that treatment effects varied for these factors.&nbsp;</p><p>The percentage of patients who died within 3 years due to COPD-related causes was 6.0% for placebo, 6.1% for salmeterol, 6.9% for FP and 4.7% for <em>RESPIRA</em>.</p><p><em>RESPIRA</em> reduced the rate of moderate to severe exacerbations by 25% (95% CI: 19% to 31%; p&lt;0.001) compared with placebo.&nbsp; <em>RESPIRA</em> reduced the exacerbation rate by 12% compared with salmeterol (95% CI: 5% to 19%, p=0.002) and 9% compared with FP (95% CI: 1% to 16%, p=0.024).&nbsp; Salmeterol and FP significantly reduced exacerbation rates compared with placebo by 15% (95% CI: 7% to 22%; p&lt;0.001) and 18% (95% CI: 11% to 24%; p&lt;0.001) respectively.</p><p>Health Related Quality of Life, as measured by the St George&rsquo;s Respiratory Questionnaire (SGRQ) was improved by all active treatments in comparison with placebo.&nbsp; The average improvement over three years for <em>RESPIRA</em> compared with placebo was -3.1 units (95% CI: -4.1 to -2.1; p&lt;0.001), compared with salmeterol was -2.2 units (p&lt;0.001) and compared with FP was ‑1.2&nbsp;units (p=0.017).</p><p>Over the 3 year treatment period, FEV<sub>1</sub> values were higher in subjects treated with <em>RESPIRA</em> than for those treated with placebo (average difference over 3 years 92mL, 95% CI: 75 to 108 mL; p&lt;0.001).&nbsp; <em>RESPIRA</em> was also more effective than salmeterol or FP in improving FEV<sub>1</sub> (average difference 50 mL, p&lt;0.001 for salmeterol and 44mL, p&lt;0.001 for FP).</p><p>The estimated 3 year probability of having pneumonia reported as an adverse event was 12.3% for placebo, 13.3% for salmeterol, 18.3% for FP and 19.6% for <em>RESPIRA</em>&nbsp; (Hazard ratio for <em>RESPIRA</em> vs placebo: 1.64, 95% CI: 1.33 to 2.01, p&lt;0.001). There was no increase in pneumonia related deaths; deaths while on treatment that were adjudicated as primarily due to pneumonia were 7 for placebo, 9 for salmeterol, 13 for FP and 8 for <em>RESPIRA</em>.&nbsp; There was no significant difference in probability of bone fracture (5.1% placebo, 5.1% salmeterol, 5.4% FP and 6.3%<em> RESPIRA</em>; Hazard ratio for <em>RESPIRA</em> vs placebo: 1.22, 95% CI: 0.87 to 1.72, p=0.248).&nbsp; The incidence of adverse events of eye disorders, bone disorders, and HPA axis disorders was low and there was no difference observed between treatments.&nbsp; There was no evidence of an increase in cardiac adverse events in the treatment groups receiving salmeterol.</p><p><strong>Mechanism of action:-</strong></p><p><em>Respira</em> contains salmeterol and fluticasone propionate which have differing modes of action.&nbsp; Salmeterol protects against symptoms, fluticasone propionate improves lung function and prevents exacerbations of the condition.&nbsp; <em>Respira</em> can offer a more convenient regime for patients on concurrent beta-agonist and inhaled corticosteroid therapy.&nbsp; The respective mechanisms of action of both drugs are discussed below:</p><p><strong>Salmeterol:-</strong></p><p>Salmeterol is a selective long-acting (12 hours) beta2-adrenoceptor agonist with a long side chain which binds to the exo-site of the receptor.</p><p>These pharmacological properties of salmeterol offer more effective protection against histamine-induced bronchoconstriction and produce a longer duration of bronchodilation, lasting for at least 12 hours, than recommended doses of conventional short-acting beta<sub>2</sub>-agonists.</p><p><em>In vitro</em> tests have shown salmeterol is a potent and long-lasting inhibitor of the release, from human lung, of mast cell mediators such as histamine, leukotrienes and prostaglandin D<sub>2</sub>.</p><p>In man salmeterol inhibits the early and late phase response to inhaled allergen; the latter persisting for over 30 hours after a single dose when the bronchodilator effect is no longer evident.&nbsp; Single dosing with salmeterol attenuates bronchial hyper-responsiveness. These properties indicate that salmeterol has additional non-bronchodilator activity but the full clinical significance is not yet clear.&nbsp; This mechanism is different from the anti-inflammatory effect of corticosteroids.</p><p><strong>Fluticasone propionate:-</strong></p><p>Fluticasone propionate given by inhalation at recommended doses has a potent glucocorticoid anti-inflammatory action within the lungs, resulting in reduced symptoms and exacerbations of asthma, without the adverse effects observed when corticosteroids are administered systemically.</p><p>Daily output of adrenocortical hormones usually remain within the normal range during chronic treatment with inhaled fluticasone propionate, even at the highest recommended doses in children and adults.&nbsp; After transfer from other inhaled steroids, the daily output gradually improves despite past and present intermittent use of oral steroids, thus demonstrating return of normal adrenal function on inhaled fluticasone propionate.&nbsp; The adrenal reserve also remains normal during chronic treatment, as measured by a normal increment on a stimulation test.&nbsp; However, any residual impairment of adrenal reserve from previous treatment may persist for a considerable time and should be borne in mind <em>(see Warnings and Precautions)</em></p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
                <label style="float: left" for="PharmacokineticProperties">5.2. Pharmacokinetic Properties</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>There is no evidence in animal or human subjects that the administration of salmeterol and fluticasone propionate together by the inhaled route affects the pharmacokinetics of either component.</p><p>For pharmacokinetic purposes therefore each component can be considered separately.</p><p>In a placebo-controlled, crossover drug interaction study in 15 healthy subjects, coadministration of <em>SEREVENT</em> (50 mcg twice daily inhaled) and the CYP3A4 inhibitor ketoconazole (400 mg once daily orally) for 7 days resulted in a significant increase in plasma salmeterol exposure (1.4-fold C<sub>max</sub> and 15-fold AUC). There was no increase in salmeterol accumulation with repeat dosing. Three subjects were withdrawn from <em>SEREVENT</em> and ketoconazole co-administration due to QTc prolongation or palpitations with sinus tachycardia. In the remaining 12 subjects, co-administration of <em>SEREVENT </em>and ketoconazole did not result in a clinically significant effect on heart rate, blood potassium or QTc duration. (<em>see Warnings and Precautions, and Interactions</em>)</p><p><strong>Salmeterol:-</strong></p><p>Salmeterol acts locally in the lung therefore plasma levels are not an indication of therapeutic effects.&nbsp; In addition there are only limited data available on the pharmacokinetics of salmeterol because of the technical difficulty of assaying the drug in plasma due to the low plasma concentrations at therapeutic doses (approximately 200 picograms/mLor less) achieved after inhaled dosing.&nbsp; After regular dosing with salmeterol xinafoate, hydroxynaphthoic acid can be detected in the systemic circulation, reaching steady state concentrations of approximately 100 nanograms/mL.&nbsp; These concentrations are up to 1000 fold lower than steady state levels observed in toxicity studies.&nbsp; No detrimental effects have been seen following long-term regular dosing (more than 12 months) in patients with airway obstruction.</p><p>An <em>in vitro</em> study showed that salmeterol is extensively metabolised to a-hydroxysalmeterol (aliphatic oxidation) by cytochrome P450 3A4 (CYP3A4). A repeat dose study with salmeterol and erythromycin in healthy volunteers showed no clinically significant changes in pharmacodynamic effects at 500 mg three times daily doses of erythromycin.However, a salmeterol-ketoconazole interaction study resulted in a significant increase in plasma salmeterol exposure. (<em>see Warnings and Precautions, and Interactions</em>)</p><p><strong>Fluticasone propionate:-</strong></p><p>The absolute bioavailability of fluticasone propionate for each of the available inhaler devices has been estimated from within and between study comparisons of inhaled and intravenous pharmacokinetic data.&nbsp; In healthy adult subjects the absolute bioavailability has been estimated for fluticasone propionate Accuhaler/Diskair (7.8%), fluticasone propionate Diskhaler (9.0%), fluticasone propionate Evohaler (10.9%), salmeterol-fluticasone propionate Evohaler (5.3%) and salmeterol-fluticasone propionate Accuhaler/Diskair (5.5%) respectively<strong>. </strong>In patients with asthma or COPD a lesser degree of systemic exposure to inhaled fluticasone propionate has been observed. Systemic absorption occurs mainly through the lungs and is initially rapid then prolonged.&nbsp; The remainder of the inhaled dose may be swallowed but contributes minimally to systemic exposure due to the low aqueous solubility and pre-systemic metabolism, resulting in oral availability of less than 1%.&nbsp; There is a linear increase in systemic exposure with increasing inhaled dose. The disposition of fluticasone propionate is characterised by high plasma clearance (1150 mL/min), a large volume of distribution at steady-state (approximately 300 L) and a terminal half-life of approximately 8 hours.&nbsp; Plasma protein binding is moderately high (91%).&nbsp; Fluticasone propionate is cleared very rapidly from the systemic circulation, principally by metabolism to an inactive carboxylic acid metabolite, by the cytochrome P450 enzyme CYP3A4.&nbsp; The renal clearance of fluticasone propionate is negligible (&lt;0.2%) and less than 5% as the metabolite.&nbsp; Care should be taken when co-administering known CYP3A4 inhibitors, as there is potential for increased systemic exposure to fluticasone propionate.</p><p>Special Patient Populations</p><p><strong><em>RESPIRA</em></strong></p><p><strong>Accuhaler/Diskair:</strong></p><p>Population pharmacokinetic analysis was performed utilising data for asthmatic subjects (nine clinical studies for FP and five studies for salmeterol) and showed the following:</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Higher FP exposure seen following administration of <em>RESPIRA</em> (50/100 micrograms) compared to FP alone (100 micrograms) in adolescents and adults (ratio 1.52 [90% CI 1.08, 2.13]) and children (ratio 1.20 [90% CI 1.06, 1.37]).</p><p>&nbsp;</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Higher FP exposure observed in children taking <em>RESPIRA</em> (50/100 micrograms) compared to adolescents and adults (ratio 1.63 [90% CI 1.35, 1.96]).</p><p>&nbsp;</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; The clinical relevance of these findings are not known, however, no differences in HPA axis effects were observed in clinical studies of up to 12 weeks duration comparing <em>RESPIRA</em> (50/100 micrograms) and FP (100 micrograms) in both adolescents and adults and in children.</p><p>&nbsp;</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; FP exposure was similar at the higher <em>RESPIRA</em> 50/500 microgram dose compared to the equivalent FP dose alone.</p><p>&nbsp;</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Higher salmeterol exposure was observed in children taking <em>RESPIRA</em> (50/100 micrograms) compared to adolescents and adults (ratio 1.23 [90% CI 1.10, 1.38]).</p><p>&nbsp;</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; The clinical relevance of these findings are not known, however there were no differences observed in cardiovascular effects or reports of tremor between adults, adolescents and children in clinical studies of up to 12 weeks duration.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PreclinicalSafetyData">5.3 Preclinical Safety Data</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Salmeterol xinafoate and fluticasone propionate have been extensively evaluated in animal toxicity tests.&nbsp; Significant toxicities occurred only at doses in excess of those recommended for human use and were those expected for a potent beta<sub>2</sub>-adrenoreceptor agonist and glucocorticosteroid.</p><p>In long term studies, salmeterol xinafoate induced benign tumours of smooth muscle in the mesovarium of rats and the uterus of mice.</p><p>Rodents are sensitive to the formation of these pharmacologically- induced tumours. Salmeterol is not considered to represent a significant oncogenic hazard to man.</p><p>Co-administration of salmeterol and fluticasone propionate resulted in some cardiovascular interactions at high doses.&nbsp; In rats, mild atrial myocarditis and focal coronary arteritis were transient effects that resolved with regular dosing.&nbsp; In dogs, heart rate increases were greater after co-administration than after salmeterol alone.&nbsp; No clinically relevant serious adverse cardiac effects have been observed in studies in man.</p><p>Co-administration did not modify other class-related toxicities in animals.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">6. PHARMACEUTICAL PARTICULARS</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ExcipientsList">6.1 Excipients List</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Lactose (which contains milk protein).</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Incompatibilities">6.2. Incompatibilities</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>None reported.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ShelfLife">6.3. Shelf Life</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                The expiry date is indicated on the packaging.
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PrecautionsStorageConditions">6.4. Special precautions for storage</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Do not store above 30&deg;C.</p><p>Store in a dry place.</p><p>If your Accuhaler/Diskair is provided sealed in a foil overwrap, this should be discarded after the Accuhaler/Diskair is used for the first time.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ContainerContents">6.5. Nature and contents of container</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>As registered locally.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="SpecialPrecautionsDisposal">6.6. Special precautions for disposal and other handling</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Your Accuhaler/Diskair may be providedin a sealed foil overwrapwhich provides moisture protection.&nbsp; If so, the foil overwrapshould only be opened when you are ready to use the Accuhaler/Diskair for the first time. Once removed/opened the foil overwrap should be discarded.</p><p>The Accuhaler/Diskair releases a powder which is inhaled into the lungs.</p><p>The device is opened and primed by sliding the lever.&nbsp; The mouthpiece is then placed in the mouth and the lips closed around it.&nbsp; The dose can then be inhaled and the device closed.</p><p>A dose indicator on the Accuhaler/Diskair indicates the number of doses left.</p><p><strong>Instructions for use of your <em>Respira</em> Accuhaler/Diskair</strong></p><p><strong>CLOSED</strong></p><p>When you take your Accuhaler/Diskair out of its box and remove any foil overwrap that may be present, the Accuhaler/Diskair will be in the closed position.</p><p><br /><img src="data:image/png;base64,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" alt="" width="208" height="177" vspace="0" hspace="0" border="0" style="width:208px;height:177px;margin-top:0px;margin-bottom:0px;margin-left:0px;margin-right:0px;border:0px solid black;" /></p><p><strong>OPENED</strong></p><p>A new Accuhaler/Diskair contains 28 or 60 doses individually protected doses of your medicine, in powder form.&nbsp; The dose indicator tells you how many doses are left.</p><p><img src="data:image/png;base64,iVBORw0KGgoAAAANSUhEUgAAAMAAAACoCAIAAAA5GXZnAAAAAXNSR0IArs4c6QAAAARnQU1BAACxjwv8YQUAAAAJcEhZcwAADsMAAA7DAcdvqGQAAA1JSURBVHhe7ZJZFuM4CEV7/5uuxvBMETRE1mQ7xf3IgQdmiv77EwQDxAMKhogHFAwRDygYIh5QMEQ8oGCIeEDBEPGAgiHiAQVDxAMKhogHFAwRDygYIh5QMEQ8oGCIeEDBEPGAgiHiAQVDxAMKhogHFAzxTz+g//471qffCpIZlPj9A+EhVEFqAsIFkPRv84NXwN/7CWJlkJeAcA5kGBD4l/iFnfHvGRBIQPgTxKog9RPETqCeQP11Xrwn/igGUgLCJ1BzICMHMnIgg4HEQGIg/SjvWw9/CwMpAWEG0gnUTxArg7xPEDuBykBqm/bVvGYr/AkMpASEPxMgnUAtIAmSSYhYAXkMJAZSg/h2XrAMrl69OzJMDnwG0gnUAkg6gZqAsAGBz1BJIeC/nEevgUtXb50mpAohogBpGJRjIDGQjAi/Yc7X8dAFWo7rcsQl4BuFgGRAoAuUMCDwGYKUjASHEYWA/zYeN3fLNV2OcwlRCPgMpBOoXaDECVQGUk6Ek7hEqryFBw0tRyTgF7AJLl9cAj4DqVAWsSvgSwMCDKRc37pLpMrzecq4LbezOdYmxCXg5xQBqgGBNvCNAYETqMkkcAouAT9JeDj3D9p4L5vjPqm7gogCpE8QK4O8TxBjIDGQylOJS8BPFDUezs1T2pOVsDnWJuouIQoB/wSqAYEyyDMgcAI1NwCcXA78nCJAfSp3ztdyIJtjbcLZ1iVEIeAbhYA0BmoxkBhI5fHEJeAzkHIinEdyz3CNd7FpJZuou4QoBHwDAhfBxwYEkjEI+G0KASlJg/Mwbhir8Rw2rcUmsi4B/wTqCdRm8NkJ1BMnikvAL0wFiYH0manG09g9U+MhbJqzxSCsTtRdQhQB0jAox0BinCIuAZ+B1DxkVrydrQM1nsDmNNoVl0iV6UgLAj7jFHEJ+CdQyzoBiUVYz2DfNO4QWVxOo62utYVUWU3asaQQ8E+gMpBOoLIuvw9h0yi6fAWb02ITzq64m0m7lxQB0glUBtIJ1PtWc+yY4+vCLsG6JZuo2Na9kXQSUQj4DCQGkgEBBhLj3LtYPkS6uSIhAn6S3B6ClaTdTnYeEQVIJ1AZSAYEGHFFv5G1E+iqiigK1CQzdWF9C8F6GDxyZjbRBUgGBE6gnkC9e+W17XU9WVUQRYH6mSk2UXGtTVj7gbhpHRIVICUgfAL17sUX9pbFeFnfRUQBkhHhnxUUF3IurAfjZi4haQrUBButpK1mVWNZj3CuIKIC1ehXXViPx03egnxiQeAE6k1HWNVV95HdCHEtCHyGnFJ3Cec+n3SFS8jnFtXF2MySrrIMb/e3vrgWBBhIuXz4SUHCuW8hXWQErTaxZjvzW8o+RNZ1IMZAYpziXCErvoXpk8s1CPi7mN9PdyjtI7oClYFkROdaSvpbWDE/X2vrWSY3k+ntGmJbRLcg8BlKFUsl9BbqC3az+TKTm9mjWDtFogKkE6jVQ9Sjb2HRFjuPM7PT8Z/z6GoI4joQMyDQsHxLzltYsQtfcdOJZraRoXV03uJA3BJIurLwpeSHs2iXbSea1uZ4AufQ1nZIyIJAM31fPZZF6ywqmzKth4zr5hbXgVgv4xWeRvdGfM6/QD1JlRXM6SELEFl3LovK3siljfiuf4Ga09VYypwGdlZrr2Bp8Vto3Ijvei2zMX+ECQ3suGIsZUOLzXy9m0sQtwSSTBr8NUyoLiNumFXY02Un9dPZqNiEuCkIf+aLvYgJ1TdMadnZaw+VA6peycnS/eFVRkuvni9lc7sNlG6oYjZaQfK7P7/EaGkabul8KZvbbSB7Q1XSUAWu9PdDsVVZwWjppcNl2d9xNcf//LmUuqmuQDJkdVFSfRajdddNVuI40vamS3HrqFvSBXLrCYKkEfBnM1S3cTJJy4KMi3R/+EzsOmq7HclNEV0TxEjh3GJ0kKG6lckkpED9BDEDAt9oz3wFdh2x3YLkOkWwejZBsGnTGaqbHWtkXPlWgJTja8KLsLuIYRVFRAI+YxUXsti06QzVdWNVBpWQA7EcyKgeBdbLsYuIXd/aApVxriVNnshQXTuWm1Lcq+Bjw1X9XdgtxFD3KtkPj+oM/AX0l7aT2RFFJ+A3g88YSCclEdZrsSuI3b0UfWi/ta7Vp9NfWke086noED0LMgwIMJAKlVPlRdiNxFC3Dy3i6jh3Lv2ldazUEMi1QDUgYEDgBKrR6+67cIvobzfHLZIKWXEi/aVlLB3OTnmMzMBvA98wkBin1N234FaQXyv2kVYYr1mnv7pMZn8Fsq3bgVQg4DNWsTZh7VfghhfXiiPYOlx77XH6q+twajh7HFctdWHN7rsUN6rYThzBlppVs0J/Ax1Up1RlLq6sdUv6Y3FDqm3FcbjJAfyV9PfQEXVQNabDrQ6sW7cfiBtPbSvOglvtOEV/Dx1Rf8VYh23RYj8KN5W666Y9DrH+FP0NdDgxeNrl4xLaxXV0tnXvxQ1jXWuvYGlxob+BLm9/98Cd0c72dbraN+LGsK6117G6RX913d/+boObo6O1CWcL8DeS9rVuGl3H0kZDpWUy/RVjG7ajtYmsS8BfTNrLKc7dwLp2Q3VlLB1u81EI6mibtrgCpKmg9Gdxpzh3ClLTgdhJVpzCUFEdy/5uhkf429e5REkRIPWCKgykE6jV2cYpFUz16a2F0aIylv3dD/V1rVsUQkQHYgWQZEDAgIAJwf9W/CpSUCpbNKq24NwpjFbUKe3vfniKj9aiEPAZSOUhEa6C1ASEk4SsOI7UzBZX0YVUn8iEcjrTivnayXYXkYB/ApWB1AVKMJAMJX0cLVuqz52PkEtw7jhzyulYx9SzR2yn1FqmIuB/glgXKPEJYsvuoMXVyKIhm1PJ72NOuWOPz3HV3Uyl7zHiCaQyyDMgUAZ5DKQ1aP3GRjZt+mzTytFkOpy19/O1tYynQO0CJU6grsR2aezIoyGz8ZN2Zpc7Z1VjP+2tJTMF4U8QS0B4C65dY3ceE5mNn7Qzf38ZV4C0ne7WMnYdpG7HtW4fxmY2ftLOqnNMH/Qqtw8wl3Sd9gVt5vSzrLry7f8fDXD7DLNIF7m0nWZe+qqRJSdeMWgHT5hhnOwW7avZzBUHWXJiN7QCaSO3NJ1Idn6+5aFnoxbNdPZE5lck3NCEs7exv+NESpPrUqUEwUb5iyV3WFP0nFXmJsQlnLuBze1mURpbdPubQroNOXcuS+q6idPpXcJSdvaaQmVg0TXq0o7PGPjVUrNYVd3Nna7Bq63dTdnWaJz6qDbqbOsSqbKIVT3cAqVlSvpc9nQZ5LhXdU6Jao66qhDiEvDXs7CTW6O01YZtj4tuvOlVWsaTBE3jL/5+Ii4BfyNrW9qVKhuW9IlsaNEBn+QAfgFJyGaKSMDfztrGbrfKnpXQFFbXv8pxFwZ+Gc1xyfz1/UstnyBdG1bC0nMcx37AuYlLk2iy+0T121k+hFvVuY5KaJB63w3IAAT8BjTffaX6E9gxh1vYuY5KaJB1lSvwrgfwm9FP3Ldc7IZFSmwa5dIVKqERFpVN4eUApIvoh2mF7pqL2DeN25zc0i0qoRGm1JTZ6iC1C1shLZUqt7N1ILf/carCRSqhbq4WlBmyIGMqtrK1lVR5AltnSu+SKkpJ76bSyyGZBPxm8NnFD/HN+ZUaFpvwKHbPlB4iVZSS3s3XgjzLhaaSr0Btnly+IqwrtqWkP4EbxkrPkSpCSe+mXq2xnaQJkHJ8jQrwq/mV0O3cMxmf7qN1qghZsZtKNe7f1EszxSBEd2R1ySfgM6liqYSewG3DZa+WVVKxm1KpS13SzNLnKkoCIa6SFS316BO4c77s+VIxzemmVOpSi0oRFxJFgHSSFR1fE57AzSOW7mj1bEIf2VJX61fyKWSj2UyXU6Il5wk8YsrSsfjUANIY2TpXi9fzbZRsdcUmxK3TmPYEnjJo/bizDprWqVc+ZsqBcAGbIPkE/AYuJd/Og2bNHjordpOtDytHNvp1HpvwNdlCyZfyn8Czxl19QVffuSnZaP0Tgqsi52uyYr96EU+ceN0pXeWvXSTfgVgVTWvPb8x8Gs8desVNXc2O+o2faNrXfEr4mvNkHj26HLcOUttwn1z9nGj8RNKOZtX8rwnP5wXTy5UJ+AYEmv8Dm2ztdho/kTTukM+vhN7FT+zQ/GfYzMZPHI1fSVo2mcSs/lJ+aJOGP8bmfE3O0vJVqQW5TvkBfmqfr/+QTahnZrGfV9AcMfijAxF/jB/cqvJv2VApp4J8TsAvIAmSKYj+k/zmbqW/zYrZhEa4/AF8g4il6O/xy0um/6J1XagDLl8ESb/Oj++JP/P8O9UgrC1w4jXw5T/MP3EC/NsMJPOARCfEDS7xb10NL4XfCixGokEH/+jt8HDi6QwTFwyGiAcUDBEPKBgiHlAwRDygYIh4QMEQ8YCCIeIBBUPEAwqGiAcUDBEPKBgiHlAwRDygYIh4QMEQ8YCCIeIBBUPEAwqGiAcUDBEPKBgiHlAwRDygYIh4QMEQ8YCCIeIBBUPEAwqGiAcUDBEPKBgiHlAwRDygYIh4QMEQ8YCCAf78+R8Ak+Ynqy7aDAAAAABJRU5ErkJggg==" alt="" width="192" height="168" vspace="0" hspace="0" border="0" style="width:192px;height:168px;margin-top:0px;margin-bottom:0px;margin-left:0px;margin-right:0px;border:0px solid black;" /></p><p>&nbsp;</p><p>Each dose is accurately measured and hygienically protected.&nbsp; It requires no maintenance - and no refilling.</p><p>The dose indicator on top of your Accuhaler/Diskair tells you how many doses are left. Numbers 5 to 0 will appear in RED, to warn you when there are only a few doses left.</p><p>The Accuhaler/Diskair is easy to use. When you need a dose, just follow the five simple steps illustrated:-</p><p>1. Open.</p><p>2. Slide.</p><p>3. Inhale.</p><p>4. Close.</p><p>5. Rinse.</p><p>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <strong>How your Accuhaler/Diskair works</strong></p><p>Sliding the lever of your Accuhaler/Diskair opens a small hole in the mouthpiece and unwraps a dose, ready for you to inhale it. When you close the Accuhaler/Diskair, the lever automatically moves back to its original position, ready for your next dose when you need it. The outer case protects your Accuhaler/Diskair when it is not in use.</p><p>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; 1.&nbsp; Open - How to use the Accuhaler/Diskair.</p><p>To open your Accuhaler/Diskair, hold the outer case in one hand and put the thumb of your other hand on the thumbgrip. Push your thumb away from you as far as it will go.</p><p><img src="data:image/png;base64,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" alt="" width="296" height="330" vspace="0" hspace="0" border="0" style="width:296px;height:330px;margin-top:0px;margin-bottom:0px;margin-left:0px;margin-right:0px;border:0px solid black;" /></p><p>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; 2.&nbsp; Slide.</p><p>Hold your Accuhaler/Diskair with the mouthpiece towards you. Slide the lever away from you, as far as it will go - until it clicks. Your Accuhaler/Diskair is now ready to use. Every time the lever is pushed back, a dose is made available for inhaling. This is shown by the dose counter. Do not play with the lever as this releases doses which will be wasted.</p><p><img src="data:image/png;base64,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" alt="" width="305" height="350" vspace="0" hspace="0" border="0" style="width:305px;height:350px;margin-top:0px;margin-bottom:0px;margin-left:0px;margin-right:0px;border:0px solid black;" /></p><p>3.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Inhale</p><p>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; -&nbsp;&nbsp;&nbsp; Before you start to inhale the dose, read through this section carefully.</p><p>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; -&nbsp;&nbsp; Hold the Accuhaler/Diskair away from your mouth. Breathe out as far as is comfortable. Remember - never breathe into your Accuhaler/Diskair.</p><p>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; -&nbsp;&nbsp; Put the mouthpiece to your lips. Breathe in steadily and deeply - through the Accuhaler/Diskair, not through your nose.</p><p>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; -&nbsp;&nbsp;&nbsp; Remove the Accuhaler/Diskair from your mouth.</p><p>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; -&nbsp;&nbsp;&nbsp; Hold your breath for about 10 seconds, or for as long as is comfortable.</p><p>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; -&nbsp;&nbsp;&nbsp; Breathe out slowly.</p><p><img src="data:image/png;base64,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" alt="" width="295" height="314" vspace="0" hspace="0" border="0" style="width:295px;height:314px;margin-top:0px;margin-bottom:0px;margin-left:0px;margin-right:0px;border:0px solid black;" /></p><p>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; 4.&nbsp; Close</p><p>To close your Accuhaler/Diskair, put your thumb in the thumbgrip, and slide the thumbgrip back towards you, as far as it will go.</p><p>When you close the Accuhaler/Diskair, it clicks shut. The lever automatically returns to its original position and is reset. Your Accuhaler/Diskair is now ready for you to use again.</p><p><img src="data:image/png;base64,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" alt="" width="295" height="286" vspace="0" hspace="0" border="0" style="width:295px;height:286px;margin-top:0px;margin-bottom:0px;margin-left:0px;margin-right:0px;border:0px solid black;" /></p><p>5. Rinse</p><p>Afterwards, rinse your mouth with water and spit it out.</p><p>If you have been instructed to take two inhalations you must close the Accuhaler/Diskair and repeat stages 1 to 4.</p><p><strong>REMEMBER</strong></p><p>Keep your Accuhaler/Diskair dry.</p><p>Keep it closed when not in use.</p><p>Never breathe into your Accuhaler/Diskair.</p><p>Only slide the lever when you are ready to take a dose.</p><p>Do not exceed the stated dose.</p><p>Keep out of reach of children.</p><p>&nbsp;</p><p>Not all presentations are available in every country.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="AuthorizationMarketingHolder">7. MARKETING AUTHORISATION HOLDER</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Manufactured by:
Glaxo Operations UK Ltd.* - Ware - UK 
Glaxo Wellcome Production, Evreux, France 
Packed by: Glaxo Saudi Arabia Ltd. * - Jeddah – KSA
*member of the GlaxoSmithKline group of companies  
For:
SPIMACO
Al-Qassim Pharmaceutical Plant
Saudi Arabia

            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="RevisionDateText">8. DATE OF REVISION OF THE TEXT</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                28 February 2019
            </div>
        </div>
    </div>
</div>

            }    </div>
    <div id="f-div" class="box-data">
        
<div class="row clearfix rtl">
    <div class="container-fluid">
        <!-- Basic Example -->
        <div class="col-lg-6 col-md-6 col-sm-6 col-xs-6">
            <div class="header">
                <h2>صورة المنتج على الرف</h2>
            </div>
            <div class="body">
                <div id="carousel-example-generic" class="carousel slide" data-ride="carousel">
                    <!-- Indicators -->
                    <ol class="carousel-indicators">
                        <li data-target="#carousel-example-generic" data-slide-to="0" class="active"></li>
                        <li data-target="#carousel-example-generic" data-slide-to="1" class=""></li>
                        <li data-target="#carousel-example-generic" data-slide-to="2" class=""></li>
                    </ol>
                    <!-- Wrapper for slides -->
                    <div class="carousel-inner" role="listbox">
                        <div class="item active">
                            
                                <img src="/images/nodrugimags.png">
                        </div>

                    </div>

                    <!-- Controls -->
                    <a class="left carousel-control" href="#carousel-example-generic" role="button" data-slide="prev">
                        <span class="glyphicon glyphicon-chevron-right" aria-hidden="true"></span>
                        <span class="sr-only">Previous</span>
                    </a>
                    <a class="right carousel-control" href="#carousel-example-generic" role="button" data-slide="next">
                        <span class="glyphicon glyphicon-chevron-left" aria-hidden="true"></span>
                        <span class="sr-only">Next</span>
                    </a>
                </div>
            </div>
        </div>
        <!-- #END# Basic Example -->
        <!-- With Captions -->
        <div class="col-lg-6 col-md-6 col-sm-6 col-xs-6">
            <div class="header">
                <h2>الصورة الاساسية</h2>
            </div>
            <div class="body">
                <div id="carousel-example-generic_2" class="carousel slide" data-ride="carousel">
                    <!-- Indicators -->
                    <ol class="carousel-indicators">
                        <li data-target="#carousel-example-generic_2" data-slide-to="0" class=""></li>
                        <li data-target="#carousel-example-generic_2" data-slide-to="1" class="active"></li>
                        <li data-target="#carousel-example-generic_2" data-slide-to="2"></li>
                    </ol>
                    <!-- Wrapper for slides -->
                    <div class="carousel-inner" role="listbox">
                        <div class="item active">
                                <img src="/images/nodrugimags.png">
                        </div>
                    </div>
                    <!-- Controls -->
                    <a class="left carousel-control" href="#carousel-example-generic_2" role="button" data-slide="prev">
                        <span class="glyphicon glyphicon-chevron-right" aria-hidden="true"></span>
                        <span class="sr-only">Previous</span>
                    </a>
                    <a class="right carousel-control" href="#carousel-example-generic_2" role="button" data-slide="next">
                        <span class="glyphicon glyphicon-chevron-left" aria-hidden="true"></span>
                        <span class="sr-only">Next</span>
                    </a>
                </div>
            </div>
        </div>
        <!-- #END# With Captions -->
    </div>
</div>


    </div>

    <!-- #END# Tabs With Custom Animations -->
</div>
        <a style="background-image: url('../images/banner.png');"
           class="scroll-top">
            <img style="margin: 15px;" src="/images/icons/up-arrow2.png" width="35">
        </a>

        <div class="footer navbar-fixed-bottom">
            <small style="color: white; margin-left: 30px;">All Rights Reserved - SFDA &copy; 2020</small>
            <br class="visible-xs visible-sm"><br class="visible-xs visible-sm">

        </div>
    </section>


    <script src="/lib/json2/json2.js?v=w3DjWhUtDqy3bSJKv285C-2kagUtW9F64T9z3xRah8g"></script>
    <script src="/lib/jquery/dist/jquery.js?v=w4hyv6-vmv08RC2hK00wXgxDziKII9paMAbU_M-5dgY"></script>
    <script src="/lib/bootstrap/dist/js/bootstrap.js?v=T574NvJTWc-Pan8hAmnXXc0eZFiqKRp7xQ3sz5QiFOk"></script>
    <script src="/lib/moment/min/moment-with-locales.js?v=5f0RFtuChrGi6osDzegxXWf5yOkmx45i7J9fM1p6P5w"></script>
    <script src="/lib/jquery-validation/dist/jquery.validate.js?v=ZDzsHzuLAtqQVxXwbgRtfAPXQ7UAoJRXBAUDvc9G9CI"></script>
    <script src="/lib/blockUI/jquery.blockUI.js?v=KKcUNqwNyTLaXzvuMyFk6JisiQq6Hk7ZtrciXnEf3Z0"></script>
    <script src="/lib/toastr/toastr.js?v=s1ewxfN8Vn23TAVRLUk8XiQUAw6uWhhuPO9dmtYzUiA"></script>
    <script src="/lib/sweetalert/dist/sweetalert.min.js?v=aPktydUv1rN3mouQeXoKi3ioFTIQlULuqYeoTAA2ihY"></script>
    <script src="/lib/spin.js/spin.js?v=b1plKpQIB-XuGyjWec42MhmhpPzEPzFI3OC8Ia0XIoc"></script>
    <script src="/lib/spin.js/jquery.spin.js?v=i7H7HL08ldqUANgfQInE7LlU2uWUdQMCJ-Q7-_zLutY"></script>
    <script src="/lib/bootstrap-select/dist/js/bootstrap-select.js?v=tXulJKckrq2j2wo8a9hvmXLDEQwhGviPTIYmEzy1dNI"></script>
    <script src="/lib/jquery-slimscroll/jquery.slimscroll.js?v=ESVSX4dkOxamaRoYfcqPM2FfErhgfxS60fp1Fa8ou1w"></script>
    <script src="/lib/Waves/dist/waves.js?v=ZOMv1vwqpT_ezNZGhvr9jJTr_jqu3lYHB7vmpxD7HmA"></script>
    <script src="/lib/push.js/push.js?v=w347yqiscLjM_TxUKpqeUA1LDR3w5vshQpxpTsgkLhE"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/abp.js?v=EjNSmvtPSqCVK_xG_aTvOp8hmVM_7vwyd3hg45CAMGk"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.jquery.js?v=XEXcdRYb4eN3XoQCbnM-BSR6UifHRLsXYDIVFZ7Oc6Q"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.toastr.js?v=h3viOCmHM1K7HnYUuJPDvLchk2Ge8CoKvl6ZJfICgII"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.blockUI.js?v=vMuHbqHh635SKL2RG2qsGGCDyHg1yFeGqhPKpS34g4k"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.spin.js?v=djoKib6ssm5DDzbXLe5pD7ayfFg3siaoEk-BFYzQlvI"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.sweet-alert.js?v=fPp3O_ILaqD0UHiR721w1i4iBtxo3NH7yfldI5dg0_I"></script>
    <script src="/js/admin.js?v=nakObLuf3yPs2VlWrIris5w-48c36X3YIRrxIis7IKQ"></script>
    <script src="/js/main.js?v=x_HDlXByl0okIi4i04d4Q_fNr85GPQi1W8gjs82s-n8"></script>
    <script src="/view-resources/Views/Shared/_Layout.js?v=36YkLzPJaGejZMB10f2T6f1rMVIzDKq96kjfcnxcLVg"></script>


        <script src="/lib/jquery-validation/src/localization/messages_ar.js?v=6kzy-p-PtvkHPWdHWyjMOIfwhBFlUYYv9jnF7zJnpUI"></script>

    <!-- Dynamic scripts of ABP system (They are created on runtime and can not be bundled) -->
    <script src="/AbpServiceProxies/GetAll?v=638865394571695575" type="text/javascript"></script>
    <script src="/AbpScripts/GetScripts?v=638865394571695575" type="text/javascript"></script>
    <script src="/lib/signalr-client/signalr.min.js?v=1yGr-J4NjYMQVt6LP6vocjHIWhO-BFQLfdCs8x1Mv-U"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.signalr-client.js?v=jTdZBAadu6DXq0iDTFX6vsn4q6bFhKm3XfN8Jz6dSmg"></script>
    
    <!-- View specific scripts -->
    
    <script src="/view-resources/Views/Home/Index.js?v=mAIakROmG_IlahImCtfrMSdaLPTG5Uoh6Z0hM1g3cxw"></script>
    <script src="/view-resources/Views/Home/Result.js?v=0pEgOuTQc8ZyJaaOpJCG7ytkKSCkzEMYCHEJfKDWu4k"></script>
    <script src="/view-resources/Views/Home/DrugsSearch.js?v=04aRniTG_ClH5tABzf7EDwQgWVpkDNpjeJUDSGvOK_Y"></script>

</body>
</html>